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Abstract  
Prostate cancer (PrCa) is the most commonly diagnosed cancer and the third most common 
cause of cancer-related morbidity in Australia. However, much of the underlying biology of 
the disease remains poorly understood. PrCa can be classified into two distinct stages, 
androgen-responsive and castrate-resistant, with poor treatment outcomes and metastasis 
common in the latter. PrCa is diagnosed through the prostate specific antigen test (PSA) 
and/or digital rectal examination (DRE). However, the latency of symptoms often means 
patients are identified relatively late in the disease which is compounded by the inaccuracy of 
the diagnostic methods. Moreover, treatment options remain relatively unsophisticated, 
especially for castrate-resistant forms of PrCa. 
Remodelling of the extracellular matrix (ECM) has emerged as an important factor in a range 
of cancers. Proteoglycans (PGs), including versican (VCAN) and other hyalectans, represent 
key structural elements of the ECM where they interact with other important molecules 
including the glycosaminoglycan hyaluronan (HA) and the cell surface receptor CD44. These 
hyalectans are known to be regulated through cleavage by the proteolytic actions of A 
Disintegrin-like And Metalloproteinase domain with Thrombospondin-1 motif (ADAMTS) 
family members. An alteration in the balance between PGs and ADAMTS enzymes has been 
proposed to be a key driver of cancer progression. This is made more complex by the ability 
of ADAMTS members to exert both pro- and anti-tumor roles, with some effects independent 
of their catalytic function.  
This Thesis has investigated the potential role of ADAMTS-15 on key phenotypes of PrCa. 
Both wild-type and catalytically-inactive forms of ADAMTS-15 were overexpressed in two 
human PrCa lines, LNCaP and PC-3, which represent models of androgen-responsive (early 
stage) and castrate-resistant (late stage) PrCa respectively. Overexpression of wild-type 
16 
 
ADAMTS-15 significantly decreased proliferation and migration that was not observed with 
the catalytically-inactive mutant. 
The LNCaP cell lines expressing wild-type and catalytically-inactive ADAMTS-15 were 
injected into male NOD/SCID mice to assess the role on tumor growth, with a group of 
castrated mice used to evaluate the effect of androgens on ADAMTS-15 mediated effects. 
Non-castrated mice injected with wild-type ADAMTS-15 demonstrated increased survival 
compared to those injected with catalytically-inactive ADAMTS-15 or control cell lines. 
However, no difference in survival was observed when castrated mice were injected with 
wild-type or catalytically-inactive ADAMTS-15.  
To further investigate the potential clinical relevance of the ADAMTS-15/VCAN interaction, 
patient samples were analyzed for expression of ADAMTS-15, VCAN and the VCAN 
bioactive fragment versikine. Co-localization between ADAMTS-15 and VCAN, was 
significant in Gleason grade 7 samples, and between ADAMTS-15 and versikine in Gleason 
grades 6 and higher.  
Collectively, the results presented in this Thesis suggest a role for ADAMTS-15 in tumor 
suppression, possibly through decreasing cell migration and proliferation in the early stages 
of PrCa where androgens are still required for growth. This required the presence of a 
functional metalloproteinase domain and, given the co-localization between ADAMTS-15 
and VCAN in clinical samples, a key substrate is likely to be VCAN.  
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1.1 Prostate cancer  
1.1.1 Overview 
Prostate cancer (PrCa) represents the most common cancer-related morbidity affecting men 
in the United States (1). An estimated 186,000 men were diagnosed with PrCa in 2008, with 
this number estimated to increase to 220,800 in 2015 (2, 3). While the estimated economic 
burden of PrCa already stood at US$11.5 billion in 2010 (4), this is also set to rise. The 
overall frequency of PrCa diagnosis has increased, which has been attributed to both an 
increased awareness of PrCa along with development of more accurate diagnostic techniques. 
For example, in Australia 194 per 100,000 males were diagnosed with PrCa in 2009 
compared to 79 per 100,000 in 1982. In Australia, 9 in 10 men will survive 5 years from 
diagnosis, meaning PrCa has the highest survival rate of all common cancers, which also 
includes lung and melanoma (5). However, 3,294 men still succumbed to the disease in 
Australia in 2011, underpinning the need for further improvements in detection and treatment 
(5).   
1.1.2 The prostate   
The prostate gland is located below the bladder with connections to the seminal vesicles (6). 
The primary function of the prostate gland is to produce fluid that aids in the protection and 
nourishment of sperm, but it also plays a role in control of urine flow and in the metabolism 
of testosterone to its metabolite 5α-dihydrotestosterone (DHT) (5, 7). The prostate gland can 
be subdivided into four areas: the transitional, peripheral and central zones, as well as the 
anterior fibromuscular stroma (Figure 1.1) (6). While all areas play a role in normal prostate 
function, the transition and peripheral zones largely give rise to benign prostatic hyperplasia 
(BPH) and carcinoma of the prostate, respectively. Within these zones there are two distinct 
epithelia, glandular epithelium and stratified epithelium, the latter further divided into basal 
23 
 
and columnar layers. The basal layer contains low cuboidal cells that form the proliferative 
section of this epithelium, from which PrCa is initiated and where it is maintained (8, 9).  
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Figure 1. 1: Location and structure of the prostate gland 
The prostate gland is located in front of the rectum under the bladder and can be 
divided into four major areas, the central, peripheral and transitional zones and the 
anterior fibromuscular stroma. The majority of PrCa originate from cells in the 
peripheral zone. 
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1.1.3 Biology of prostate cancer 
The biology of PrCa is complex, with the disease typically divided into two distinct stages. 
Initially, androgen-insensitive cells form a transition cell layer that becomes ‘androgen-
responsive’ through expression of the androgen receptor, with these cells able to secrete the 
prostate specific antigen (PSA) (8). However, over time a subset of these cells acquire the 
ability to proliferate without androgens, despite the continued expression of the androgen 
receptor. This so-called ‘castrate-resistant’ phase facilitates metastasis to secondary sites 
distant from the source of androgens, principally including bone, lung, liver, pleura and 
adrenal glands (8, 10, 11). Possible causes for resistance include mutations in the androgen 
receptor or constitutive signaling through co-activator pathways (11).   
1.1.4 Genes involved in prostate cancer 
A leading risk factor for PrCa is a family history of the disease, with several genes linked to 
PrCa incidence. Amongst these is hereditary prostate cancer locus-1 (HPC-1) located on 
chromosome 1q24-25 (12-14). Heterozygote germline mutations in HPC, which encodes 
RNaseL, are highly linked to PrCa amongst family members, opening the possibility of its 
use as a diagnostic and potential therapeutic marker (13). Other genes associated with PrCa 
include EPAC2, MSR1, CHEK2, CAPZB, vitamin D receptor and PON1 (12). However, the 
low incidence of variants of these genes in PrCa limits their diagnostic value (12, 13). 
Moreover, these genes likely represent only a fraction of the genes that contribute to PrCa.             
1.1.5 Current diagnostic methods  
PrCa is difficult to detect in its early stages due to lack of symptoms, which allows it to 
progress to more malignant stages prior to diagnosis and treatment. Currently there are two 
accepted detection methods, assessment of serum PSA levels and physical examination, 
specifically the digital rectal examination (DRE) (15, 16). The PSA test analyzes patient 
serum for the presence of a prostate-specific serine protease that is released when the prostate 
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becomes leaky, such as during PrCa development (17, 18). Serum PSA at greater than 4.0 
ng/ml is considered indicative of PrCa prompting consideration of appropriate treatment, 
PSA levels between 4.0 ng/ml and 2.5 ng/ml require close monitoring with regular yearly 
checks, whereas levels of less than 2.5 ng/ml are managed by screening every two years (15, 
16). However, males may have a leaky prostate in the absence of PrCa, leading to false 
positives that represent a major limitation of this technique (16). The DRE is an invasive 
procedure with a general practioner required to physically insert a hand digit into the rectum 
of the patient to feel for physical changes in the prostate (19, 20). This also has limitations, 
including low sensitivity and human error, which also leads to mis-diagnosis (21, 22). The 
combined use of PSA and DRE provides a more definitive diagnosis prior to confirmation 
using biopsies (16, 19). Less invasive methods of detection are rapidly becoming available, 
which include Positron Emission Tomography (PET), Computed Tomography (CT) and 
Magnetic Resonance Imaging (MRI) scanning (23-27). The main disadvantages of these 
approaches are the cost, the limited availability of equipment, and the lack of information 
regarding accuracy. Urine tests are also being developed as an alternative to blood testing 
(28). 
1.1.6 Grading and staging of prostate cancer 
It is essential to be able to differentiate PrCa to allow informed decisions regarding 
appropriate treatments. The Gleason grading system scores a cancerous growth on the basis 
of pathology as determined by microscopic examination of a biopsy (29-31). This system 
scores the two most common histopathological types from 1 (normal differentiation) to 5 
(undifferentiated) (29, 30).  
Recently a new grading system has been proposed that has improved prognostic value (30, 
32). Briefly, a Gleason score ≤ 6 represents prognostic grade I, a Gleason score of 3+4=7 
represents prognostic grade II, a Gleason score of 4+3=7 represents prognostic grade III, a 
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Gleason score of 4+4=8 represents prognostic grade IV, and a Gleason score 9 represents 
prognostic grade V. (32). In addition, PrCa is staged on the basis of its size and extent of 
growth within or beyond the prostate based on the TNM (tumor, nodes, metastasis) scoring 
system (33).  
1.1.7 Current treatments 
There are four major clinical responses to PrCa diagnosis. These include watching and 
waiting, androgen deprivation therapy (ADT), surgical removal or treatment with 
chemotherapy and/or radiotherapy (34-39). The decision on the appropriate treatment option 
is informed by PSA levels, Gleason grade, stage and responsiveness to androgens and taking 
into consideration the potential side effects of some treatment options. Active surveillance 
(watching and waiting) requires regular PSA tests and physical examinations to monitor 
tumor status and to trigger initiation of other treatment options should the cancer progress 
(39). 
 Elimination of androgens has been shown to cause transition cells to undergo apoptosis, 
thereby inhibiting PrCa progression (8).  This can be achieved via physical castration, also 
called radical prostatectomy (RP), which has long been used as a primary treatment option 
for PrCa, although the impact of potential side-effects post-surgery need to be considered 
against the benefits (40). The side-effects include urinary incontinence, and irregularities in 
bowel function and sexual function, although nerve sparing and improvements in organ 
preservation during surgery have been shown to decrease their likelihood (36, 41-43).   
Another approach is so-called ‘chemical castration’, which disrupts the pituitary-testicular 
axis that mediates testosterone production. Both agonists and antagonists of luteinizing 
hormone-releasing hormone (LHRH) can achieve inhibition of testosterone production, 
including gonadotropin-releasing hormone (GnRH) (44).  
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Other treatments block androgen biosynthesis. For example, abiraterone inhibits testosterone 
synthesis by blocking the cytochrome P450 c17 (CYP17) enzyme. Treatment in the adrenal 
gland, testes and within prostate tumors has been shown to increase survival after treatment 
with docetaxel in castrate-resistant PrCa (45-49). However, limitations include increased 
risks of cardiac disorders and hypertension (46). Androgen receptor antagonists are another 
option (50), although it has been shown that mutations to the androgen receptor can turn the 
androgen receptor inhibitor antagonists bicalutamide and hydroxyflutamide into agonists 
(51). Therefore, alternate methods are required to prevent PrCa metastasis. A major limitation 
of all ADT approaches is the high incidence of relapse and little guarantee of complete 
remission (34, 52). 
A further option for treatment is chemotherapy and/or radiotherapy, which are usually only 
used in the castrate-resistant stages of PrCa. The gold standard in chemotherapy for PrCa is 
docetaxel, a member of the taxane family that acts as a potent inhibitor of cell division (53-
55). However, development of resistance is common and the chances of remission high (54). 
Treatment with other chemotherapeutic drugs, such as mitoxantrone and cabazitaxel with 
prednisone, have also been trialled but showed poor efficacy and in the case of cabazitaxel 
with prednisone, elicited a high incidence of neutropenia (55-58). Radiation therapy for PrCa 
can be delivered in two forms: external beam radiotherapy (EBRT) or via brachytherapy 
(BR) implants of either low-dose-rate or high-dose–rate radiotherapy (37, 59). A major 
limitation of EBRT is organ movement that can lead to other tissues being affected (59). BR 
overcomes this limitation, by mediating local radiation, thereby reducing ‘off-target’ effects 
(37, 59, 60). Recent evidence has shown that a combination of both EBRT and BR led to a 
31% reduction in the risk of reoccurrence and no change in toxicity compared to EBRT alone 
(59, 61).     
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Although current treatments have benefit in reducing cancer progression, further work is 
needed to identify PrCa in its earlier stages, and to identify targets for the development of 
more specific therapeutic agents for this disease.    
1.2 The extracellular matrix 
1.2.1 Overview 
The extracellular matrix (ECM) has important functions in determining tissue architecture, 
forming a penetrable barrier surrounding tissues that can be dynamically remodelled (62). 
Recent studies have linked ECM remodelling with unfavourable outcomes in several cancers, 
including melanoma, ovarian, cervical, breast, prostate and colon cancer (63-68). For 
example, the ECM has been shown to play an integral role in maintaining the architecture of 
the stroma, loss of which can contribute to epithelial to mesenchymal transition, a key step in 
cancer progression (69). Whether these changes occur in PrCa remains to be determined. 
1.2.2 Extracellular matrix structure  
The ECM is composed of a basement membrane and interstitial matrix, both of which contain 
fibrous proteins and numerous proteoglycans (PGs) (62, 70). PGs contribute to various 
biological functions such as tissue structure maintenance and regulation of cell proliferation, 
adhesion, migration and differentiation (71). A defining feature of PGs is the presence of 
covalently linked glycosaminoglycan (GAG) side chains. Four classes of GAGs have been 
implicated in cancer progression: heparan sulphate (HS), chondroitin sulphate (CS), keratan 
sulphate (KS) and hyaluronan (HA) (72). A pericellular matrix (PCM) resides in close 
proximity to the cell membrane (73-76), which aids in communication between the cell and 
the ECM including mechanosensing, and also regulates proliferation and migration (74, 76-
79). The composition of PCM is unique to different cell types, but the major component is 
typically HA (73-79). 
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1.2.3 Versican and other hyalectans 
Versican (VCAN) is a HA-binding PG belonging to the hyalectin family, which include 
aggrecan (ACAN), neurocan (NCAN) and brevican (BCAN), collectively representing key 
components of the ECM (80).VCAN allows the ECM to maintain a loose hydrated structure 
during key remodelling events, including those modulated in carcinogenesis such as cell 
adhesion, migration, proliferation and angiogenesis (80, 81).  Five VCAN isoforms are 
produced through alternative splicing, including full-length VCAN (V0) and the variants V1, 
V2, V3 and V4 (80-85). All forms of VCAN consist of globular N-terminal and C-terminal 
domains, termed G1 and G3 respectively, with the differences between the isoforms located 
in the intervening GAG region (Figure 1.2).  The G1 domain consists of an immunoglobulin-
like motif along with linking sequences that act to facilitate binding of HA with CD44 (84, 
86, 87). The G3 domain contains two epidermal growth factor (EGF)-like repeats along with 
a lectin-like motif and a complement-binding region. The EGF-like motifs can directly 
regulate proliferation through binding of the epidermal growth factor receptor (EGFR) (84, 
86-88).  
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Figure 1. 2: Structure of versican variants 
Schematic representation of the VCAN variants V0-V4 generated by alternate 
splicing, showing their constituent domains, which include G1, G3 and interestingly 
GAG domains and their interaction with HA and CD44. 
 
 
 
 
32 
 
VCAN isoforms possess alternate GAG attachment, GAG-α and GAG-β, which differ in the 
number of CS side chains: 12-17 for GAG-α and 5-8 for GAG-β (83, 84, 89). Full-length 
VCAN (V0) contains both GAG-α and GAG-β sub-domains (83, 84). V1 contains only the 
GAG-β subdomain, and V4 just part of GAG-β (83, 84, 90). In contrast, V2 contains only the 
GAG-α subdomain, with the V3 isoform possessing neither of the GAG subdomains, and so 
is strictly a glycoprotein rather than a PG (83, 84). These differences in the GAG region are 
thought to lead to VCAN isoforms having different properties. The V0 and V1 isoforms have 
been shown to be widely expressed throughout the body, whereas the V2 and V3 isoforms 
were primarily found in the central nervous system (83, 91-93). V4 expression remains 
poorly characterized (90).   
Interestingly, VCAN is known to be regulated by the A Disintegrin-like And 
Metalloproteinase domain with Thrombospondin-1 motif (ADAMTS) family. ADAMTS-1, -
4, -5, -9, -15 and -20 have been previously shown to cleave VCAN (94-97) within the GAG-β 
domain forming a bioactive fragment termed versikine (G1-DPEAAE) (Figure 1.3) (95, 98, 
99). The role of this fragment is poorly studied in cancer and is an emerging area of research, 
with recent investigations showing a role for regulation of immune factors in myeloma (100).   
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Figure 1. 3: Generation of the bioactive fragment versikine 
Formation of the bioactive form of VCAN by ADAMTS proteoglycanases, which 
cleave the V1 isoform in the N-terminal region of the GAG-β region to generate the 
75 kDa fragment called versikine.   
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Other related hyalectans include ACAN, NCAN and BCAN. ACAN is been shown to be an 
important component of cartilage with decreased ACAN leading to impaired of joint function 
(101-106). A major constituent of brain tissue is NCAN, which has roles in adhesion and 
migration, with the addition of exogenous NCAN shown to increase neurite outgrowth in 
culture in the absence of heparin (107-115). BCAN is a brain-enriched HA-binding protein 
that potentially functions in the terminal differentiation of neurons (116-122).  
1.2.4 Hyaluronic acid 
HA is a major non-proteinaceous component of the ECM stroma and is known to play 
important roles in cell migration, invasion and metastasis (123-127). HA elicits its effects 
through interactions with CD44 and receptor for hyaluronic acid-mediated motility 
(RHAMM, CD168), both of which are expressed on the cell surface (Figure 1.4) (124, 126, 
128, 129). This interaction stimulates activation of ERK1/2 via the RAS/RAF/MEK pathway 
and AKT via the PI3K pathway that in turn stimulates downstream effectors such as S6K, 
4E-BP1 and HIF-1 (124, 130). CD168 may also be able to function independently of CD44 
(123, 128).  
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Figure 1. 4: Hyaluronan-mediated signalling and its regulation 
Schematic representation of HA binding to membrane bound CD168 or CD44/CD168 
complexes and the subsequent activation of various intracellular signalling pathways. 
The intracellular synthesis of HA by hyaluronan synthase (HAS), and its negative 
regulation via extracellular hyaluronidase (HYAL)-mediated cleavage is also shown. 
Adapted from Weigelt and Downward (130). 
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1.2.5 ADAMTS family 
The metzincin super-family represents a large group of zinc-dependent metalloproteinases 
characterized by a conserved catalytic motif, which encompasses three histidine residues that 
bind a zinc ion and a conserved glutamate residue required for acid-base catalysis (131, 132). 
Amongst the metzincins, the ADAMTS family comprises 19 members (Figure 1.5).  These 
secreted enzymes participate in key ECM remodelling events associated with proliferation, 
cell-cell fusion and morphogenesis (98, 133, 134). ADAMTS family members each consist of 
an N-terminal protease region containing a pro-domain, metalloproteinase domain and a 
disintegrin-like domain. Individual ADAMTS members are defined by differences in the C-
terminal ancillary region, with variation in the presence and number of thrombospondin type-
1 motifs, presence of a Gon-1 module, protease and lacunin domains, complement domains, 
mucin/PG domains and pro-collagen N-propeptidase sequences (133, 135, 136). ADAMTS-
1, -4, -5, -8, -9, -15 and -20 show proteoglycanase activity toward hyalectans (135-137), with 
VCAN and ACAN being major substrates, whereas ADAMTS-2, -3 and -14 have alternate 
roles as pro-collagen N-propeptidases, essential for collagen formation and maturation (133). 
In contrast, ADAMTS-13 cleaves von Willebrand factor (vWF), a key component in 
coagulation (133, 138, 139). 
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Figure 1. 5: Structure of ADAMTS family members 
Schematic representation of the 19 members of the ADAMTS family with constituent 
domains indicated. Note ADAMTS-5 and ADAMTS-11 represent the same identified 
protein. 
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1.2.6 Role of hyalectan proteoglycans in cancer 
Emerging as a key factor in cancer progression is the role of ECM disruption, with a growing 
body of evidence indicating that VCAN is an important player in this process. VCAN has 
been shown to be up-regulated in a range of cancers, including malignant myeloma, 
glioblastoma, prostate, breast, ovarian, gastric, laryngeal, pancreatic, testicular germ-cell and 
cervical cancer (90, 140-163). Moreover, accumulation of VCAN has been shown to 
correlate with poor prognosis in many tumors, including glioblastoma, as well as breast and 
prostate carcinomas (63, 90, 148, 149). However, in ovarian cancer, decreased plasma VCAN 
correlated with higher grades of metastatic cancer (150). The association between VCAN and 
colon cancer remains controversial. Studies have indicated that increased VCAN (and the PG 
decorin) promoted colon cancer progression through binding with HA (164), which itself 
accumulated in many cancers (125). However, de Wit et al demonstrated that levels of 
VCAN (and the PG lumican) correlated with positive outcomes in stage II and III colon 
cancer patients (165). One possible explanation for the differences observed is that alternative 
VCAN isoforms were involved (164).  
Breast cancer cells have been shown to express VCAN, with increased expression associated 
with metastasis (90, 91). Moreover, expression of the VCAN G3 domain in breast cancer cell 
lines promoted tumor growth and increased distant metastases, which correlated with 
increased levels of EGFR on the cell surface (166). In another study, expression of VCAN 
G3 led to increased vascular endothelial proliferation and increased bone metastasis (167). 
In PrCa, VCAN was up-regulated along with the PGs syndecan-1, perlecan, decorin, 
biglycan, NG2/CSPG4, serglycin and lumican, as well as CD44 (63). Other studies have 
shown that increased VCAN correlated with increased PSA levels and poorer prognosis in 
this disease, including an increased risk of metastasis after RP (144, 145). The VCAN V1 
isoform was also demonstrated to promote PrCa cell motility (94, 143) and decreased cell 
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attachment to fibronectin coated substrate (144). VCAN accumulation was also observed in 
the stroma during PrCa – possibly in an androgen-responsive manner – and acted as an 
indicator of disease relapse in clinically localized PrCa (143, 168). The interaction between 
HA and VCAN has recently been demonstrated to contribute to PrCa through regulation of 
cell adhesion and migration (84, 86), with evidence that PrCa cells use VCAN and HA to 
create a PCM that facilitates migration (143). CD44 is up-regulated along with VCAN and 
HA in PrCa (141, 169-171). However, it is not well understood whether VCAN binding to 
CD44 plays a role in PrCa progression, and whether this is dependent or independent of HA 
(172).  
Less is known about other hyalectans, but there is some clear evidence that they also 
contribute to the pathology and/or progression of cancer. Indeed, in the case of ACAN this 
appears to be as a tumor suppressor. Thus, reduced ACAN expression was shown to correlate 
with a poorer prognosis and increased metastasis in laryngeal cancer (101), while 
homozygous deletion of ACAN is linked to the development of Epstein-Barr virus induced 
classical Hodgkin lymphoma (173). 
Altered NCAN expression has been identified in alcohol induced hepatocellular cancer and 
astrocytoma (118, 174). NCAN signals through its C-terminal fragment, which has been 
demonstrated to increase in the rate of neural outgrowth (118). NCAN can activate the cell 
surface receptors and the fellow heparan sulphate proteoglycans (HSPGs) syndecan-3 and 
glypican-1, along with the L1 glycoprotein, thereby modulating cell adhesion and growth 
(118, 175). As previously mentioned, NCAN expression is observed in low-grade 
astrocytoma, however, this is down-regulated in metastatic tissues (118). This suggests that 
NCAN may have a role in the initial establishment of cancer but is not required for metastatic 
growth. A single nucleotide polymorphism in the NCAN gene is associated with steatosis in 
heavy drinkers, leading to an increased risk of patients developing hepatocellular cancer 
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(174). Moreover, NCAN was more highly expressed in alcohol-induced compared to 
hepatitis C induced hepatocellular carcinomas (174). While the exact mechanism is unknown 
it has been suggested to involve lipid metabolism (174).  
BCAN is a major factor in the progression of glioma and astrocytoma cancers (116-118). In 
glioma, expression of BCAN was up-regulated when compared to normal brain tissue (116, 
117). Moreover, overexpression of BCAN increased the aggressiveness of gliomas, while its 
knock-down decreased the aggressiveness of late stage cancer (117). BCAN is also known to 
activate the EGFR, thereby increasing cell adhesion and fibronectin secretion (116). In 
contrast, breast cancer cells showed reduced expression of BCAN compared to normal tissue 
due to gene methylation (176).  
1.2.7 Role of ADAMTS enzymes in cancer 
Amongst ADAMTS members, ADAMTS-1, -2, -4, -5, -6, -8, -9, -12, -13, -14, -15, -16, -18, -
19, -20 have been implicated in cancer progression (Table 1).  
ADAMTS-1 (METH-1), first discovered in cancer cachexia, has been shown to possess both 
pro- and anti-metastatic properties. ADAMTS-1 is expressed in lung, breast, pancreatic, 
prostate and hepatocellular cancers (177-185). In esophageal cancers, increased ADAMTS-1 
production due to loss of transforming growth factor beta (TGF-β) signals induces EGF-
mediated metastatic pathways (183). In contrast, in lung cancer, ADAMTS-1 promoted tumor 
development at least in part due to increased TGF-β leading to recruitment of fibroblasts 
and/or myofibroblasts (179, 183). Furthermore, vascular endothelial growth factor (VEGF)-A 
was able to up-regulate ADAMTS-1 and one of its activators, matrix metalloproteinase 
(MMP)-15, allowing VCAN cleavage and increased angiogenesis (186). Alternatively, 
ADAMTS-1 has been identified as a possible tumor suppressor in PrCa, since its expression 
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was lower in patients with metastasis and in hormone-refractory tumors, with low ADAMTS-
1 expression correlating with increased angiogenesis (182).  
A possible mechanism for the dual role of ADAMTS-1 in cancer progression is the 
differential activity of full-length versus N- or C-terminally cleaved forms of the protein 
(179). Thus, full-length ADAMTS-1 has been demonstrated to promote the progression of 
murine mammary carcinoma and Lewis lung carcinoma, but the truncated form was able to 
inhibit cancer progression (187). Interestingly, both full-length and C-terminal cleavage 
fragments have been identified in hepatocellular cancer with full-length ADAMTS-1 leading 
to EGFR activation (185). Therefore, further investigations are warranted to determine how 
ADAMTS-1 cleavage is mediated and how the cleaved form exerts its differential effects.   
ADAMTS-2 has similarly been shown to have a dual role in cancer progression. For 
example, TGF-β has also been demonstrated to regulate ADAMTS-2 transcription, with up-
regulation causing enhanced cleavage of procollagens I and II, implicating ADAMTS-2 in 
bone metastasis in osteosarcoma (188-192). In contrast, exogenous ADAMTS-2 reduced the 
proliferation, attachment and survival of human endothelial cell lines, with these effects 
preceded by dephosphorylation of myosin light chain and ERK1/2 that was not observed in 
fibroblasts. Enforced ADAMTS-2 expression was further shown to mediate anti-angiogenic 
and anti-tumorigenic effects independently of its catalytic activity (193). The domain 
responsible for this effect remains to be determined.  
ADAMTS-4, which is closely related to ADAMTS-1, has also been shown to have a dual 
role in cancer. ADAMTS-4 expression has been shown to be highly up-regulated in benign 
PrCa with the addition of TGF-β shown to dramatically increase expression in prostatic 
stromal cells (181). Expression of full-length and C-terminal fragments of ADAMTS-4 in 
B16 melanoma cells promoted growth and angiogenesis in mice, but not the catalytically-
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inactive E362A mutant (194), identifying the thrombospondin-type-1 repeat domain and the 
enzymatic activity as being critical (194). C-terminal processing has also been detected in 
hepatocellular carcinoma cell lines, leading to multiple forms of ADAMTS-4 in these cells 
(185). ADAMTS-4 (along with ADAMTS-5) can also cleave BCAN at its Glu395-Ser396 site, 
which may also play a critical role in mediating its tumor-promoting effects (195-197). 
However, ADAMTS-4 also exerted anti-angiogenic effects in human umbilical vein 
endothelial cells, by blocking the interaction of VEGF to VEGF receptor 2 (198), an effect 
also observed with ADAMTS-1 (199), leading to inhibition of angiogenesis. Further 
investigations of the pro- and anti-tumor effects are warranted. 
ADAMTS-5, well known for its ability to cleave the PGs ACAN, VCAN and BCAN can also 
act as a tumor suppressor protein through anti-angiogenic effects (200). ADAMTS-5 
expression was found to be down-regulated in both breast and colorectal cancer, which in the 
latter case was mediated by hypermethylation of its promoter (201, 202). Interestingly, 
ADAMTS-5 expression was down-regulated in the human PrCa cell lines PC-3 prostate 
carcinoma derived cell line, DU145 and lymph node adenocarcinoma of the prostate LNCaP, 
along with the human hepatocellular cell line HCC (181, 185). Furthermore, ADAMTS-5 
overexpression decreased the growth of melanoma tumors in mice, with the autocatalytic 
fragments p45 and p60 demonstrated to inhibit angiogenesis in vitro, suggesting that 
ADAMTS-5 can act as a tumor suppressor independently of its proteoglycanase activity 
(203). In contrast, in laryngeal cancer ADAMTS-5 (and -4) expression was increased (204), 
suggesting a pro-tumor role, probably related to the function of these family members as 
aggrecanases.  
Recently emerging as a possible tumor suppressor gene in breast cancer is ADAMTS-6. 
Overexpression of ADAMTS-6 was shown to suppress migration, invasion and 
tumorigenesis while knocking-down expression reversed these effects. Furthermore, high 
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expression of ADAMTS-6 in breast cancer biopsies found a high degree of cancer free 
survival based on high expression of ADAMTS-6. This suggests a role as a possible 
biomarker for ADAMTS-6 in breast cancer, although further investigations are needed to 
understand the mechanism involving the ERK pathway (205). 
ADAMTS-8 (METH-2) has also emerged as a tumor suppressor in several types of cancers. 
Its expression has been shown to be down-regulated in brain, breast, gastric, non-small cell 
lung, head and neck squamous and pancreatic carcinomas when compared to matched normal 
tissues, largely due to promoter methylation (206-208). Restoration of ADAMTS-8 in 
nasopharyngeal carcinoma cells and oesophagus squamous cell cancer lines decreased cell 
clonogenicity and migration but increased apoptosis, which appeared to be due to antagonism 
of the EGFR-ERK receptor pathway (206). Functional studies have indicated that down-
regulation of ADAMTS-8 in brain tumors leads to inhibition of apoptotic pathways, thereby 
promoting cancer progression (207). Recently ADAMTS-8 expression was shown to be 
down-regulated in gastric cancers via methylation, suggesting a role for ADAMTS-8 in 
invasion and metastasis (208). Further investigations are required to understand the exact role 
of ADAMTS-8 in specific cancers. 
ADAMTS-9 expression has been demonstrated in kidney and ovarian cancers but its effects 
in these cancers has not been investigated further (209). However, ADAMTS-9 has been 
shown to be down-regulated in malignant and invasive breast carcinomas compared to non-
neoplastic cell lines (202). Furthermore, expression of ADAMTS-9 was shown to inhibit 
tumor growth through suppression of angiogenesis in esophageal squamous cell and 
nasopharyngeal carcinomas, mediated by a reduction in the pro-angiogenic factors VEGF-A 
and MMP-9 (210). Decreased ADAMTS-9 expression was also observed in lymph node 
metastasis of nasopharyngeal carcinomas, which may serve as a useful biomarker for 
progression of this cancer (211).      
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ADAMTS-12 is believed to act as a tumor suppressor in a variety of cancers independent of 
its metalloproteinase domain (212). ADAMTS-12 expression in MDCK (Madin-Darby 
canine kidney), bovine aortic endothelial and lung carcinoma cells resulted in decreased 
tumorigenicity, diminished ability to form tubules (in the presence of VEGF) and decreased 
sub-cutaneous tumor size, through inhibition of the RAS-MAPK pathway (213). Enforced 
expression of ADAMTS-12 significantly inhibited growth of the breast cancer cell line MCF-
7 in vitro and in vivo (214). Interestingly, ADAMTS-12 was shown to interact with fibulin-2, 
with the co-expression of fibulin-2 reducing matrigel invasion and mammosphere formation 
(214). Tumor suppressor properties were also observed in the context of SCID mice injected 
with A549 lung cancer cells, where overexpression of ADAMTS-12 resulted in decreased 
tumor growth (213). Expression of ADAMTS-12 in colon cancer cells (CCD-18Co 
fibroblasts) was shown to be increased in the presence of TGF-α and TGF-β1 in stromal cells 
adjacent to malignant epithelial cells compared to normal paired normal tissues (215). 
Accumulation of stromal ADAMTS-12 has also been demonstrated to increase with cancer 
grade, although this may still reflect a tumor suppressor role (216). Importantly, inhibition of 
tumor angiogenesis has been observed in Adamts12 knockout mice (212). These studies 
emphasis ADAMTS-12’s role in modulation of the microenvironment, which impacts on 
tumor development.    
ADAMTS-15 has been shown to act as a tumor suppressor in breast and colorectal cancers 
(217, 218). Indeed, expression of ADAMTS-15 has been shown to correlate with improved 
prognosis in breast cancer patients, and led to reduced motility of breast cancer cell lines 
(MDA-MB-231) and decreased formation of tubules from endothelial cell lines (217, 219). 
Interestingly motility was shown to be independent of its catalytical activity with 
metalloproteinase-inactive ADAMTS-15 also decreasing migration (219). ADAMTS-15 
expression also reduced breast cancer metastasis to the liver but, interestingly, increased 
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metastasis to the lung, again suggesting a more complex role. (219). Inactivating mutations in 
ADAMTS-15 were identified in a subset of colorectal and pancreatic cancer patients (220, 
221). Loss of ADAMTS-15 in colorectal cell lines resulted in increased tumor growth both in 
vitro and in vivo, which could be reversed with the re-expression of ADAMTS-15 (218). 
Interestingly, inhibition of ERK pathway activation was observed in the HCT-116 colon 
cancer cell lines expressing ADAMTS-15, which was reversed in SW-620 cells when 
ADAMTS-15 was knocked-down (218). However, expression of ADAMTS-15 in colon 
cancer samples did not correlate with cancer grade (218).  
Regulation of ADAMTS-16 has also been demonstrated to correlate with cancer progression 
in esophageal squamous cell carcinoma, whereby knock-down inhibited cell growth and 
invasion (222). However, the mechanism remains unknown and requires further investigation 
(222).  
Mutations and promoter methylation of ADAMTS-18 have been observed in a range of 
cancers, including nasopharyngeal, melanoma, gastric, colorectal and pancreatic cancers 
(223-225). Melanoma cell lines carrying inactivating mutations in ADAMTS-18 showed 
reduced cell adhesion and increased migration both in vitro and in vivo, indicating a cancer-
specific tumor-enhancing function (224). However, in gastric, colorectal and pancreatic 
cancers, ADAMTS-18 mutations did not correlate with disease progression (223). Therefore, 
further investigations into such mutations are necessary to elucidate the role of ADAMTS-18 
in cancer progression and to determine if this family member may also have a dual role. 
Finally the ADAMTS-14 and -19 genes having been shown to be methylated in colon and 
gastrointestinal cancers, respectively, when compared to normal tissue, leading to reduced 
expression (226, 227). Moreover ADAMTS-14 has recently been implicated in oral cancer 
where specific short nucleotide polymorphisms in this gene were shown to interact with 
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environmental factors (228). Furthermore, ADAMTS-20 has been demonstrated to be down-
regulated in colon cancer, with ramifications for tumor progression through effects on the 
ECM (229). These three ADAMTS require further investigations to identify their exact role, 
but further highlight the importance of regulation of the ECM on cancer progression.   
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Table 1: ADAMTS members implicated in cancer  
ADAMTS Cancer Biological outcome Reference 
-1 
Breast, pancreatic, hepatocellular, 
lung and prostate 
Mutations in the metalloproteinase domain mediated 
dual role in cancer progression 
(177-187) 
-2 Osteosarcoma 
Elevated expression increased cleavage of pro-
collagens I and II 
(188-193) 
-4 
Hepatocellular, melanoma and 
prostate 
Increased expression led to elevated binding to VEGF, 
promoting angiogenesis 
(181, 185, 194-198) 
-5 
Breast, colorectal, melanoma and 
prostate 
Decreased expression during cancer progression, 
possibly relieving anti-angiogenic function 
 (200-204) 
-6 Breast 
Suppressed expression led to decreased migration 
invasion and metastasis.  
(205)  
-8 
Brain, breast, gastric non-small-
cell lung, head and neck 
squamous and pancreatic 
Methylation-mediated decreased expression resulted in 
inhibition of apoptosis, invasion and metastasis 
(206-208) 
-9 
Kidney, ovarian, breast,  
esophageal squamous cell and 
nasopharyngeal 
Decreased expression led to decreased tumor growth 
and angiogenesis  
(202, 209-211) 
-12 Lung, breast and colon 
Decreased tumor growth with possible interactions 
with fibulin 2 
(212-216) 
-14 Colon, oral and gastrointestinal Methylated when compared to normal tissue (226-228) 
-15 Breast, colorectal and prostate 
Decreased expression associated with reduced cell 
motility in breast carcinomas 
(217-220) 
-16 Esophageal squamous cell 
Knockdown led to inhibition of cell growth and 
invasion 
(222) 
-18 
Melanoma, gastric, colorectal and 
pancreatic 
Mutations led to decreased cell adhesion and increased 
cell motility, but not correlating with progression 
 (223-225) 
-19 Colon and gastrointestinal Methylated when compared to normal tissue (227) 
-20 Colon Decreased expression (229) 
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1.2.8 ADAMTS regulators 
Some ADAMTS proteases proteins are known to be inhibited by members of the tissue 
inhibitor of metalloproteinases (TIMP) family, which bind specifically to the active site 
within the metalloproteinase domain (181, 230, 231). Four TIMPs have been identified: 
TIMP-1, -2, -3 and -4, with TIMP-1 and -3 well-characterized (231). Most studies 
investigating the interactions of TIMPs and ADAMTS proteins have focused on cartilage 
and, in particular, the degradation of the PG ACAN (232, 233). In contrast, studies into the 
role of TIMP-mediated regulation of ADAMTS in a cancer setting are relatively limited. 
However, expression of TIMP-1 (along with MMP-2) has been suggested as a predictor of 
pancreatic cancer progression (234). TIMP-1 (and MMP-9) was also highly up-regulated in 
the urine of patients with bladder cancer (235). Equally, TIMP-3 expression has been shown 
to be up-regulated in both hepatocellular carcinoma cells and in benign PrCa cell lines (181, 
185). In general, these effects are consistent with TIMPS acting to inhibit tumor-suppressor 
functions mediated by ADAMTS members. 
1.3 Rationale for the project  
Current research has indicated that the ECM plays an important role in the progression of 
many cancers, with particularly important roles played by the hyalectan PGs, especially 
VCAN. It has further demonstrated the close relationship between ADAMTS, the hyalectans 
and the ECM, and suggested that disruption of this relationship represents a potential 
mediator of cancer progression. The hyalectan VCAN was found to be highly up-regulated 
along with the HA receptor CD44 in PrCa (63). Indeed, current research indicated VCAN 
could serve as a potential indicator of PrCa progression, with increased levels of VCAN 
correlating with increased PSA levels, along with a poor prognosis and an increased risk of 
developing metastatic PrCa after RP (140-146). Additionally, VCAN accumulation has also 
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been demonstrated in the stroma of PrCa, acting as an indicator of disease relapse in 
clinically localized PrCa (63, 143, 168).  
The V1 isoform, of VCAN appears to also promote PrCa cell motility (94, 143). Furthermore, 
VCAN accumulation in prostatic fibroblasts has been shown to lead to a significant decrease 
in cell attachment to the fibronectin coated substrate (144). The interaction between HA and 
VCAN has recently been demonstrated to contribute to PrCa through regulation of cell 
adhesion and migration; however, the interaction is not fully understood (84, 86).  
VCAN has been shown to be regulated by the ADAMTS family, with ADAMTS-1, -4, -5, -9, 
-15 and -20 all demonstrated to cleave VCAN (94-97). Of these ADAMTS-1, -4, -5, and -15 
have been shown to have altered expression in PrCa progression (181, 236), with ADAMTS-
1 demonstrated to act as a tumour suppressor gene in PrCa progression (182). However, our 
understanding of the other family members remains limited. ADAMTS-4 and -5 have been 
shown to be highly up-regulated in benign PrCa (181), but are below detectable levels in 
PrCa cell lines and so may not be clinically relevant.  
Interestingly, ADAMTS-15 has been implicated in breast and colon cancer progression, 
where it has been shown to act as a tumor suppressor (217, 218). Furthermore, ADAMTS-15 
expression was shown to be up-regulated in representative late stage castrate-resistant PrCa 
cell lines (181). However, little is known about the role of ADAMTS-15 in PrCa progression. 
ADAMTS-15 has previously shown to have a weak association with the hyalectan ACAN 
(219) but ADAMTS-15 could also regulate VCAN in the context of PrCa.  
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1.3 Aims and hypothesis 
This Thesis describes studies investigating the hypothesis that ADAMTS-15 contributes to 
the molecular etiology of PrCa potentially via its effects on VCAN. 
This hypothesis will be examined by addressing the following specific aims: 
1) To determine the effect of ADAMTS-15 on key phenotypes of human prostate cancer 
cell lines in vitro and in vivo; 
2) To characterize the levels of ADAMTS-15, versican and cleaved versican in human 
prostate cancer samples.  
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Chapter 2 ~ Materials and Methods 
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2.1 Materials 
2.1.1 Suppliers 
The following companies supplied products used in this work. 
Abacus ALS Pty. Ltd., Queensland, Australia. 
Abcam, Victoria, Australia.  
Agilent Technologies, Victoria, Australia. 
Astral Scientific, New South Wales, Australia. 
Barwon Health, Victoria, Australia. 
BD Biosciences, New South Wales, Australia.  
Bioline, New South Wales, Australia. 
BioRad, New South Wales, Australia. 
Chem Supply, South Australia, Australia. 
Dako Australia, Victoria, Australia. 
Grale Scientific, Victoria, Australia.   
In Vitro Technologies, Victoria, Australia. 
Leica Microsystems, New South Wales Australia. 
Life Technologies, Victoria, Australia. 
Merk Millipore, Victoria, Australia. 
MP Biomedicals, New South Wales, Australia. 
Olympus, Victoria, Australia. 
53 
 
OriGene Technologies, Rockville, United States of America. 
Pacific Lab Products, Victoria, Australia. 
Perkin Elmer, Victoria, Australia. 
ProSciTech, Victoria, Australia. 
Qiagen, Victoria, Australia. 
Roche Diagnostics, New South Wales, Australia. 
Sapphire Biosciences, New South Wales, Australia. 
Sigma Aldrich, New South Wales, Australia. 
Thermo Fisher Scientific, Victoria, Australia. 
VWR International, Queensland, Australia. 
Zeiss, New South Wales, Australia. 
2.1.2 Products 
The sources of individual chemicals, media components, antibodies, reagents and equipment 
are provided within each method. Additional products also used in this work are detailed 
below. 
2.1.2.1 Cell materials 
2 ml Eppendorf tubes (Pacific Lab Products). 
5, 10 and 25 ml sterile pipettes (VWR International).  
50 ml tubes (VWR International). 
2.1.2.2 Cytology materials 
Wax pen (Dako Australia). 
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2.1.2.3 Animal materials 
26 gauge needles (BD Biosciences). 
1 ml syringes (BD Biosciences).  
2.2 Methods 
2.2.1 Cell culture 
Lymph node adenocarcinoma of the prostate (LNCaP) and prostate carcinoma  derived cell 
line (PC-3)were cultured in Dulbecco’s modified Eagle medium (DMEM) (Life 
Technologies) containing 10% (v/v) fetal bovine serum (FBS) (In Vitro Technologies) and 
0.1% (w/v) penicillin/streptomycin (Pen/Strep) (Life Technologies) in sterile 75 cm2 tissue 
culture flasks (VWR International). Cells were maintained in a water-jacketed Hera cell 
incubator (Thermo Fisher Scientific) at 37C supplemented with 5% CO2. Cells were 
passaged by washing with phosphate buffered saline (PBS) (Astral Scientific) before 
treatment with 0.125% (w/v) trypsin/5 mM EDTA (Life Technologies) until visually 
detached from the tissue culture surface. An aliquot was diluted (typically 1:10) into 
DMEM/10% (v/v) FBS and transferred to a fresh 75 cm2 flask (VWR International).  
2.2.2 Cell counting 
Cultures were made into a single cell suspension using trypsin treatment as described above. 
A 100 μl aliquot of this cell suspension was combined with 100 µl (w/v) trypan blue reagent 
(Astral Scientific) and viable cells were counted using a hemocytometer (Sigma Aldrich).  
2.2.3 Transfection 
Cells were grown to 70% confluence in a 75 cm2 flask in 10 ml DMEM/10% (v/v) FBS. A 45 
µl aliquot of Lipofectamine-2000 (Life Technologies) was added to approximately 600 µl 
serum free DMEM media and incubated for 5 min at room temperature under sterile 
conditions. To this mix 8 µg DNA construct was added and incubated for 20 min at room 
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temperature. The mix was added to the cells, which were incubated for 5 h at 37°C and 5% 
CO2, at which time the mix was replaced with fresh DMEM/10% (v/v) FBS. 
For stable transfections, cells were grown to 100% confluence and split 1:10 and 1:20 into 
DMEM/10% (v/v) FBS media containing 700 µg/ml Geneticin (Life Technologies) in sterile 
tissue-culture grade petri dishes (VWR International) and incubated at 37°C and 5% CO2 
until colonies were visible. Individual colonies were aspirated and transferred to a 24 well 
plate (VWR International) and grown to 100% confluency. Cells were then trypsinized 
(0.125% (w/v) trypsin/5 mM EDTA) and transferred sequentially to a 12 well plate, 6 well 
plate and finally into 25 cm2 flasks (VWR International). 
2.2.4 Cryopreservation 
Trypsinized cells were resuspended in 10 ml DMEM/10% (v/v) FBS and transferred to a 15 
ml Falcon tube (VWR International). D-methylsulphoxide (DMSO) (Thermo Fisher 
Scientific) was then added drop-wise to the tube for a final concentration of 10% (v/v) and 
the cell suspension aliquoted into 1 ml cryovials (Thermo Fisher Scientific). Cryovials were 
then stored at -80°C for 24 h and then transferred to liquid nitrogen for long-term storage.  
2.2.5 Preparation of conditioned media and cells 
Cells were grown to a density of 100,000 per well in a 6 well plate (DMEM/10% (v/v) FBS). 
Cells and media were removed from the culture dish by scraping (Thermo Fisher Scientific) 
or using 0.125% (w/v) trypsin/5 mM EDTA and placed in 1.5 ml Eppendorf tubes (Pacific 
Labs products) and centrifuged at 13,000 g for 5 min. The supernatant was then transferred to 
a fresh Eppendorf tube and stored at -80°C until subsequent use.  
2.2.6 Scratch “wound” assays 
Cells (~900,000) were aliquoted into 6 well plates in DMEM/10% (v/v) FBS and allowed to 
adhere for 12 h at 37°C and 5% CO2. A bent 200 µl pipette tip (Thermo Fisher Scientific) 
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was then used to “wound” the cell monolayer before the media was removed and cells 
washed with serum free DMEM media prior to addition of DMEM/2% (v/v) FBS. Images 
were taken at 0, 6, 12 and 24 h to assess migration using a Leica light microscope (Leica 
Microsystems). 
2.2.7 Proliferation assay 
Cells (~20,000) were aliquoted into a clear 96 well plate (VWR International) in 
DMEM/10% (v/v) FBS and incubated for 24 h and 48 h at 37°C and 5% CO2. Ten microliters 
of WST-1 proliferation reagent (Roche diagnostics) was then added to each well. Following 
incubation at 37°C and 5% CO2 for 2 h, absorbance was read using a Fusion-alpha HT 
(Perkin Elmer) plate reader at 450 nm to determine relative proliferation. 
2.2.8 Cell cycle analysis 
Cells (~80,000) were aliquoted into 6 well plates in DMEM/10% (v/v) FBS and incubated for 
12 h at 37°C and 5% CO2. Medium was replaced with 2 ml serum free DMEM medium and 
cells incubated for 24 h and 48 h at 37°C and 5% CO2 after which cells were subjected to cell 
cycle analysis using the manufacturer’s protocol (Abcam). Briefly, cells were trypsinized 
then washed once with 1 ml 1 x PBS followed by centrifugation at 500 g for 5 min. To the 
cell pellet 400 µl of ice cold 1 x PBS and 800 µl 100% (v/v) ethanol were added followed by 
suspension for storage at 4C for a minimum of 2 h and a maximum of 4 weeks. Prior to 
analysis cells were gently resuspended before being centrifuged at 500 g for 5 min, and 
washed with 1 ml of 1 x PBS. A 200 µl aliquot of propidium iodide (PI) (50 µg/ml) (Abcam) 
was then added to the cells before incubating for 20-30 min in the dark at room temperature, 
with samples loaded into individual round bottom Falcon tubes (In Vitro Technologies) for 
analysis with a  FACSCANTOTMII (BD Bioscience).   
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2.2.9 Apoptosis assay 
Cells at 100% confluency were trypsinized as above and plated out into 6 well plates in 
DMEM/10% (v/v) FBS and allowed to adhere for 12 h at 37°C and 5% CO2. Cells were then 
treated with either 0.1% (v/v) sodium azide (Sigma Aldrich) or 100 nM docetaxel (Barwon 
Health) for 24 h and 72 h, respectively. Cells were then trypsinized and washed with 5 ml of 
1 x PBS and the cell pellet resuspended in 400 µl of 1 x Annexin buffer (BD Biosciences), 
with 100 µl aliquots pipetted into 4 separate Eppendorf tubes. One tube was left alone, to the 
second 4 µl AnnexinV (FITC) (BD Biosciences) was added, to the third 4 µl PI (BD 
Biosciences) was added, and to the final 4 µl of both FITC and PI was added. The samples 
were then incubated in the dark for 15 min at room temperature, before a further 100 µl 1 x 
Annexin buffer was added. The samples were then loaded into individual round bottom 
Falcon tubes and read using the FACSCANTOTMII (BD Bioscience).   
2.2.10 Mitochondrial respiration – Seahorse assay 
Cells (~40,000) were aliquoted into a Seahorse V7 plate (Agilent) in 500 µl DMEM/10% 
(v/v) FBS media, allowing cells to adhere for 12 h at 37°C and 5% CO2. Media was aspirated 
before the cells were washed with 500 µl of running media (50 ml of unbuffered DMEM, 1 
mM glutamate, 25 mM glucose and 1 mM sodium pyruvate; pH 7.4), followed by washing 
with a further 600 µl of fresh running media. The Seahorse machine (Agilent) was calibrated 
(~30-40 min) using a sensor cartridge containing equilibration buffer and maintained at 37°C 
for 12 h in a non-CO2 incubator. A load cartridge for injection of compounds containing 75 µl 
of each compound (1 µM oligomycin, 1 µM carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP), 1 µM rotenone and 1 µM antimycin A) was prepared and 
incubated at 37°C for 15 min, prior to placement in the Seahorse machine and 
commencement of the cycle. Briefly, cells were mixed for 3 min, rested for 2 min and 
mitochondrial respiration measured for 3 min for 3 cycles before compounds were 
58 
 
sequentially injected (oligomycin, FCCP, rotenone and antimycin A) with respiration 
measured for 3 min following each addition. Once the analysis was complete, the buffer was 
aspirated and cells lysed with lysis buffer (2.4.1) before storing the plate at -80°C for 
subsequent protein estimation with the bicinchoninic acid (BCA) assay (2.4.3).       
2.3 DNA methods 
2.3.1 Transformation 
Empty vector and mouse ADAMTS-15 (wild-type) (OriGene) or mouse ADAMTS-15EA 
(catalytically-inactive, E362A (94)) containing pcDNA3.1MycHisA+ (Thermo Fisher 
Scientific) constructs were diluted to 1 ng/µl in nuclease free water (NFW) (Life 
Technologies) and 1 µl added to 50 µl of sub-cloning competent DH5α Escherichia coli (Life 
Technologies). These were placed on ice for 20 min then incubated at 42°C for 50 sec, before 
being placed back on ice for a further 2 min. To each of the tubes 450 µl of Luria broth (LB) 
(Astral) was added under sterile conditions and tubes were transferred to a shaker/incubator 
set at 37°C and 250 rpm for 1 h. Aliquots were plated on LB plates containing 100 mg/ml 
ampicillin (Sigma Aldrich) and 1.5% (w/v) agar (Astral) and incubated for 16 h at 37°C.  
2.3.2 Miniprep 
Minipreps were performed as per the manufacturer’s protocol (Life Technologies). Briefly, 
single bacterial colonies were used to inoculate 5 ml LB/100 mg/ml ampicillin cultures that 
were placed in a shaking/incubator at 37°C and 250 rpm for 16 h, and then centrifuged at 
3000 rpm for 5 min at 4°C. The supernatant was removed, and the bacterial pellet was re-
suspended in 250 µl re-suspension buffer and transferred to an Eppendorf tube. To each 
sample 250 µl lysis buffer was added before inverting 5 times and incubating at room 
temperature for 5 min. Next, 350 µl precipitation buffer was added before inverting 3 times 
and centrifugation at 12,000 g for 10 min. The supernatant was then loaded into a wash tube 
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and centrifuged at 12,000 g for 1 min, discarding the flow-through. A 700 µl aliquot of wash 
buffer was then loaded into the spin column, which was centrifuged at 12,000 g for 1 min, 
and after discarding the flow-through, re-centrifuged at 12,000 g for 1 min. The flow-through 
was again discarded, and the spin column placed in a recovery tube to which 40 µl of pre-
heated (65°C) TE buffer was added. After incubating for 1 min at room temperature, the 
recovery tube containing the spin column was then centrifuged for 2 min at 12,000 g. The 
flow-through was then placed back in the spin column before undergoing re-centrifugation 
for 2 min at 12,000 g. Miniprep samples were stored at -20C for subsequent use. 
Absorbance was determined using a Nanodrop (Thermo Fisher Scientific), with concentration 
determined from A260 = 50 µg/μl and purity evaluated from A260/280 ratios with acceptable 
purity being >1.8.  
2.4 Protein methods 
2.4.1 Protein lysates  
Cell pellets were washed once and resuspended in 1 x PBS before centrifugation at 13,000 g 
for 5 min at 4°C. Protein lysis buffer (0.05 M Tris-HCL, pH7.5, 0.001 M EDTA, 0.001 M 
EGTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 0.05 M NaF, 0.005 M NaP2O5, 0.001 M 
Na3VO4) (50 µl) containing 1:20 protease inhibitor (Roche Diagnostics) was added and the 
cell pellet resuspended before centrifugation at 13,000 g for 5 min at 4°C. The supernatant 
was then removed and placed in a new Eppendorf tube and stored at -80°C until subsequent 
use.  
2.4.2 Western blot 
Samples were thawed on ice and an aliquot mixed with 0.25 µl 0.1% (w/v) bromophenol blue 
(Astral) before incubating at 95C for 5 min. Samples were then placed on ice for 5 min 
before being centrifuged at 12,000 rpm for 15 sec. Supernatants were loaded onto gels in 1 x 
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running buffer (250 mM Tris, 1.92 mM Glycine, 0.1% (w/v) SDS), along with Precision Plus 
Protein Dual Color marker (Biorad). The gel was subjected to 60 mA per gel for 
approximately 1 h then blotted onto PVDF membrane (VWR International) at 100 mA for 1 h 
in 1 x transfer buffer (250 mM Tris, 1.92 mM glycine, 20% (v/v) methanol). The membrane 
was stained with 0.1% (w/v) Ponceau S staining solution (Sigma Aldrich) for 10 min and 
then placed under running water and visualized to confirm successful transfer of protein. The 
membrane was placed in a dark vessel containing 5% (w/v) skim milk for 1 h at room 
temperature with agitation to block the membrane. Blocking solution was removed and 
replaced with 1% (w/v) skim milk containing anti-Myc (Sigma Aldrich, # M4439) primary 
antibody and incubated at 4°C for 24 h with agitation. Following this the membrane was 
washed 3 times with 1 x Tris-buffered saline with Tween 20 (TBST) (0.05 M Tris, 0.15 M 
NaCl, 1% Tween, pH7.4) before incubation with goat anti-mouse HRP (Abacus, # 115-035-
003) secondary antibody in 1% skim milk for 1 h at room temperature with agitation. 
Following this the membrane was washed 6 times with 1 x TBST before a 1 ml aliquot of 
ECL prime (VWR International) was added for approximately 5 min. Chemiluminescence 
was detected either by film (VWR International) or using a Chemi doc (BioRad) using the 
manufacturer’s programs. To ensure equal loading of samples had occurred the membrane 
was re-probed with anti-GAPDH (Merk Millipore, # MAB374), followed by the goat anti-
mouse HRP and ECL prime (VWR International).  
2.4.3 BCA assay     
The BCA assay was carried out as per the manufacturer’s protocol (Thermo Fisher 
Scientific). Briefly, standards were prepared through serial dilutions with final concentrations 
being 2000, 1500, 1000, 750, 500, 250, 125, 25, 0 (blank) µg/ml. To a clear 96 well 
microplate 10 µl of protein sample, along with 200 µl of working reagent ((# standards + # 
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unknowns) × (# replicates) × (volume of WR per sample) = total volume WR required)) was 
added to a single well. The plate was then shaken for 30 sec and incubated at 37°C for 30 
min. The plate was cooled to room temperature and absorbance read at 562 nm on an 
xMarkTM microplate spectrophotometer (BioRad).   
2.5 RNA methods 
2.5.1 RNA extraction 
Trypsinized cells were washed in 1 x PBS and the pellet resuspended in 1 ml TRIzol (Life 
Technologies), and placed on dry ice to be stored at -80°C until subsequent use. RNA 
extraction followed the manufacturer’s protocol (Life Technologies). In brief, 120 µl of 
chloroform (Sigma Aldrich) was added per ml of TRIzol, then tubes were vortexed for 15 sec 
and incubated for 2 min at room temperature. Tubes were then centrifuged at 12,000 g for 15 
min at 4°C, allowing samples to separate into an upper clear phase and pink phase. The clear 
phase was collected and 0.5 ml isopropanol (Chem Supply) added before incubating for 10 
min at room temperature. Samples were then centrifuged at 12,000 g for 10 min at 4°C. The 
gel pellet was washed with 1 ml 75% (v/v) ethanol and centrifuged at 7,500 g for 5 min at 
4°C. The supernatant was removed allowing the pellet to dry at 65C. Samples were then re-
suspended in 30 µl NFW and placed back on a heat block for 10 min.  
Alternatively tumor samples were halved and placed in 1 ml TRIsure (Bioline) on ice. Tubes 
were then transferred to a FastPrep-24 tissue homogenizer (MP Biomedicals) and 
homogenized at 6.0 M/s for 60 sec. Samples were then transferred to -80C until subsequent 
use. Once required samples were defrosted on ice and re-homogenized before RNA 
extraction was carried out as per above protocol.  
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Once RNA was extracted absorbance was read on a Nanodrop, with concentration 
determined from A260 = 50 µg/μl and purity evaluated from A260/280 ratios with acceptable 
purity being >1.8. Samples were then stored at -80°C for subsequent use. 
2.5.2 cDNA synthesis 
Synthesis of cDNA was carried out as per the manufacturer’s protocol (BioRad). 
Approximately 1 µg total RNA was incubated with 1 µl of iScript reverse transcriptase in 20 
µl of 1 x iScript reaction mix and incubated at 42C for 30 min then 85C for 5 min, before 
storage at -20C. 
2.5.3 Reverse transcription PCR 
A 2 µl aliquot of cDNA was mixed with 0.2 µl Taq DNA polymerase (Roche diagnostics) 
and 0.5 µM of primers specific for ADAMTS15 (5-‘TCCTCTTCACCAGGCAGGAC and 5’-
GGTCACACATGGTACCCACATCA) or the house-keeping gene β-ACTIN  (5’-
GGACTTCGAGCAAGAGATGG and 5’-AGCACTGTGTTGGCGTACAG) in 50 µl 1 x 
Magnesium+ buffer (Roche Diagnostics), and amplified using the T100TM thermal cycler 
(BioRad) under the following conditions: 95C for 2 min, 35 cycles of 95C for 30 sec, 58C 
for 30 sec, 72C for 10 min before being held at 4C. Samples were run on a 2% agarose gel 
(Astral Scientific) in 1 x TAE buffer (Astral Scientific) containing SYBR safe (Life 
Technologies) at 100 volts for approximately 30 min, and visualised on a Chemidoc 
(BioRad). 
2.5.2 RNA profiling  
Real time reverse-transciprtion (RT2) PCR analysis was carried out using the RT2 profiler 
PCR human cell motility (Qiagen) as per manufacturer’s protocol. Firstly, purified RNA (0.5 
µg) was added to buffer GE (2 µl) in a total volume of 10 µl using RNase-free water, and 
incubated at 42C for 5 min to eliminate DNA then on ice for 1 min. For cDNA synthesis, 4 
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µl 5x buffer BC3, 1 µl control p2, 2 µl RE3 reverse transcriptase mix and 3 µl RNase-free 
water was added and the samples incubated at 42C for 15 min and then at 95C for 5 min 
followed by addition of 91 µl RNase-free water before placing on ice. For each 96 well RT2 
PCR array a 2.7 ml master mix was prepared, containing 1x RT2 SYBR green master mix, 
and 102 µl cDNA synthesis reaction. A 25 µl aliquot of this mix was added to each well, 
before plates were spun down for 1 min at 1000 g at room temperature and then placed on 
ice. The samples were then analyzed by qRT-PCR for 1 cycle at a duration of 10 min at 
95C, followed by 40 cycles of 15 sec at 95C and 1 min at 60C using an Mx3000P 
Stratagene thermocycler (Agilent Technologies). Raw CT values were then exported and 
analyzed online through the Qiagen PCR array data analysis system 
(http://www.qiagen.com/au/shop/genes-and-pathways/data-analysis-center-overview-page/).        
2.6 Cytology methods 
2.6.1 FITC conjugation  
Conjugation of anti-ADAMTS-15 (Sapphire Biosciences, # AB45047) was performed as per 
manufacturer’s protocol (Abcam). In brief, 1 µl modifier reagent was added to 10 µl antibody 
(100 µg) and this added to FITC mix (10 µg) followed by incubation at room temperature in 
the dark for 3 h. Next 1 µl quencher was added and the solution and mixed gently with the 
conjugated antibody was then stored at 4C in the dark until subsequent use. 
2.6.2 Immunofluorescence 
Sections were deparaffinized by washing in 2 x histolene (3 min) (Grale Scientific), 
decreasing concentrations of ethanol, (100%, 90% and 70%) (2 min each), water (30 sec) and 
1 x PBS (5 min). Sections were blocked in 10% (v/v) normal goat serum (NGS) (Life 
Technologies) for 1 h at room temperature. The primary antibodies anti-versican GAG β 
(Merk Millipore, # AB1033) and anti-V0/V1 Neo (versikine (Thermo Fisher Scientific, # 
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PA1-1748A)) were diluted in 200 μl 1 x PBS/Triton X100 (Astral) and applied dropwise to 
the section before incubating at 4°C in a humidified chamber for 24 h. Post-incubation slides 
were washed 3 times in 1 x PBS/Triton X100 or 10 min at room temperature. Slides were 
then incubated in goat anti-mouse Alexa Fluor 594 (Life Technologies, # A11012) secondary 
antibody for 1 h at room temperature in the dark, then washed 6 times for 10 min in 1 x 
PBS/Triton X 100. Alternatively, 200 µl of conjugated antibody in 1 x PBS/ Triton X 100 
was applied and allowed to incubate for 3 h in the dark at room temperature, with slides 
washed 6 times for 10 min in 1 x PBS/Triton X100. Following this 200 µl DAPI vector shield 
(Abacus) was applied to a cover slip (ProSciTech) and placed on the sections. These were 
sealed with nail polish and allowed to dry before storing at 4°C until imaging using a 
Fluoview FV10I microscope (Olympus). 
2.6.3 Hematoxylin and eosin staining 
Human prostate section slides were deparaffinized as per Section 2.6.2. After washing in 1 x 
PBS for 5 min, slides were then placed in filtered hematoxylin (Grale Scientific) for 5 min. 
Slides were then washed under running tap water for approximately 5 min and then washed 
in 1% (v/v) acid alcohol (Grale Scientific) for 30 sec, before washing under running tap water 
for 1 min. Slides were then dipped in Scott’s bluing solution (Grale Scientific) for 1 min, and 
again washed under running tap water for 5 min. Slides were then rinsed with 20 dips in 95% 
(v/v) ethanol, dipped in 100% (v/v) ethanol and then counterstained in eosin solution (Grale 
Scientific) for 5 min. Slides were then dehydrated by 5 dips in 95% (v/v) ethanol and 10 dips 
in 100 % (v/v) ethanol, and placed in two changes of histolene for 5 min each before 
mounting with DPX (Sigma Aldrich) and imaging (Zeiss, Axiocam HRC). 
2.6.4 Tissue embedding and sectioning 
Tumor samples were fixed in 4% paraformaldehyde (PFA) for 24 h and placed in embedding 
cassettes (ProSciTech) that were inverted into an embedding machine (Leica, TP 1020-1-1). 
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The machine cycled for 2 h sequentially in each of PBS x 2, ethanol (v/v) 30% x 1, 50% x 1, 
70% x 1, 90% x 1, 100% x 2, histolene x 2 and paraffin (Sigma Aldrich) x 2. Samples were 
then held in the paraffin before being removed from cassettes and positioned in wax moulds 
(ProSciTech) and placed on an ice plate to set with storage at -20°C until subsequent use.  
Tumor samples were sectioned at 5 μM using a microtome (Leica Microsystems) and placed 
in 2% (v/v) ethanol separated and transferred to a 28C water bath before positioning on a 
glass slide (ProSciTech), which was then left at 22°C to dry. 
Human prostate sections were obtained in collaboration with Dr. Elizabeth Williams and 
Prof. Ken Opeskin (St. Vincent’s Hospital) and the Australian Prostate Cancer BioResource. 
Sections were pre-cut to 5 μM and pre-fixed on slides using paraffin. 
2.6.5 Immunohistochemistry 
Immunohistochemistry was performed according to the manufacturers protocol (Abcam) and 
deparaffinized as per Section 2.6.2. Hydrogen peroxide was then added drop wise to cover 
the sections, incubating at room temperature for 10 min. Slides were then washed twice 
before blocking with a protein block for 10 min at room temperature. Slides were then 
washed once and primary antibodies anti-Ki67 (Abcam, # AB15580), anti-Caspase 3 
(Abcam, # AB4051) and anti-Myc applied overnight in a humidified chamber at 4C. Slides 
were then washed 4 times in wash buffer before the secondary biotinylated goat anti-mouse 
& rabbit antibody was applied and incubated for 10 min at room temperature. Slides were 
then washed 4 times and streptavidin peroxidase applied for 10 min at room temperature. 
Slides were then washed 4 times before DAB chromogen and DAB substrate mix (1 drop 
DAB chromogen to 50 drops DAB substrate) was applied and incubated for 5 min at room 
temperature. Slides were then subjected to hematoxylin and eosin staining (2.6.3). 
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2.7 Animal methods 
All animal work was carried out with the approval of Deakin University animal ethics 
committee under the reference number G18-2015 
2.7.1 Injection of cells 
Briefly, male NOD-SCID mice, 8-10 weeks old, were anaesthetized using isoflurane and 
injected subcutaneously into the left flank using a 26 gauge needle with 1 x 106 cells in 100 
µl 1 x PBS (PC-3) or equal volumes of 1 x PBS and matrigel (In Vitro Technologies) and 
LNCaP) (Figure 2.1). For the PC-3 cells, non-castrated mice were used while for LNCaP cell 
lines both castrated and non-castrated mice were used (Figure 2.1). 
2.7.2 Follow-up 
Mice were weighed daily following injection. Tumors were measured using callipers once 
visible, with tumor volume calculated by length x width2 x 0.5. Humane killing was 
performed via the CO2 method once tumors had reached 15 mm
3 in diameter or if significant 
(>10%) weight loss had occurred, or by 6 months for mice in which tumors had not formed. 
Animals had access to unlimited food and water from time of injection. 
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Figure 2. 1: Outline of PrCa cell line injections 
Summary of method for subcutaneous injections of male NOD/SCID mice injected 
with stable cell lines expressing ADAMTS-15, ADAMTS-15EA and pcDNA3.1 
controls in both the PC-3 and LNCaP cell lines.  
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2.7.3 Harvesting of tumors 
Tumors were surgically removed, along with other abnormal tissue. Extracted tumors were 
cut in two with half being fixed in 4% PFA for embedding (2.6.4), and half placed in TRIsure 
for RNA extraction (2.5.1).  
2.7.4 Statistical analysis and quantitation 
Analysis for all experiments used GraphPad Prism software to determine statistical 
significance with student T-test, one way ANOVA and Tukey’s post-hoc as appropriate. For 
immunofluorescence and histochemistry staining Image J software was used to determine 
localization of immunohistochemical images utilizing the intensity correlation tool and 
thresholding (237).  Co-localization analysis using the same intensity used a plugin for Image 
J software utlized the Pearson Correlation Co-efficient and Manders overlap to determine the 
difference in fluorophores 
(http://wwwfacilities.uhnresearch.ca/wcif/imagej/colour_analysis.htm).    
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Chapter 3 ~ Effects of enforced ADAMTS-15 
expression in human prostate cancer cell line models 
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3.1 Overview 
ADAMTS-15 has been reported to be highly expressed in late stage PrCa cell lines (217, 218) 
but its function in PrCa has remained unknown. This Chapter aimed to investigate the role of 
ADAMTS-15 in cell line models of PrCa. Two were chosen: LNCaP, being representative of 
the androgen-responsive or early stage of PrCa, and PC-3 being representative of the castrate-
resistant or late stage of PrCa. The strategy involved overexpression of both wild-type and 
catalytically-inactive forms of ADAMTS-15 since non-enzymatic roles had been described 
for other ADAMTS family members (193, 203, 219). The effects of overexpression on key 
cancer phenotypes including proliferation, apoptosis and migration were then analyzed.  
3.2 Constructs used in this study 
This work utilized the pcDNA3.1 (+) mammalian expression vector, which contains a 
neomycin gene under the control of the SV40 promoter with a downstream SV40 poly A site 
to permit selection of stable transfectants, a human cytomegalovirus immediate-early (CMV) 
promotor to allow for expression of proteins cloned into the downstream multiple cloning 
sites that is followed by a BGH poly A site, as well as an ampicillin resistance gene and an 
origin of replication for selection and propagation in Escherichia coli  (Figure 3.1A). Into this 
vector was cloned DNA encoding the wild-type full-length ADAMTS-15 or a 
metalloproteinase-inactive form of ADAMTS-15 (ADAMTS-15EA), which has a single 
amino acid substitution in the metalloproteinase domain (Figure 3.1B). Both were fused in-
frame to a C-terminal Myc-His tag to facilitate detection with relevant antibodies. 
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Figure 3. 1: Expression of ADAMTS-15 and ADAMTS-15EA  
A schematic representation of the pcDNA3.1 (+) expression vector (A) showing key 
features, including the multiple cloning site, the cytomegalovirus promoter (Pcmv), 
bovine growth hormone poly A sequence (BGH pA), ampicillin resistance gene 
(Ampicillin), neomycin resistance gene (neomycin) and PUC origin of replication 
(PUC ori). This was used to express full-length wild-type ADAMTS-15 and 
catalytically-inactive ADAMTS-15EA (B). The domain structure of ADAMTS-15 is 
shown in the key, with the position of the E to A mutation in the metalloproteinase 
domain highlighted in red, and the C-terminal Myc-His tag indicated. 
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3.3 Establishment of prostate cancer cell lines stably expressing wild-type 
and catalytically-inactive ADAMTS-15      
PC-3 and LNCaP cell lines were transfected with pcDNA3.1 or pcDNA3.1 containing 
ADAMTS-15 or ADAMTS-15EA using a published protocol to obtain stable cell lines (238). 
The optimal concentration of geneticin for selection was first determined as the lowest 
concentration resulting in the death of the majority of cells after 3 days and of all cells within 
2 weeks. Cells at 80% confluence were then transfected separately with each plasmid using 
Lipofectamine and left for 24-48 h before being split into petri dishes in the presence of the 
optimal geneticin concentration until colonies formed. A number of colonies were selected 
from cells transfected with each construct for subsequent expansion and analysis. Protein 
lysates were prepared and subjected to Western blot analysis using an anti-Myc antibody 
(Figure 3.2). Clones were selected based on expression of Myc tagged ADAMTS-15 and 
ADAMTS-15EA at the expected molecular weight which was not seen in pcDNA3.1 
transfectants, with GAPDH used as a loading control. Both the zymogen and mature forms of 
ADAMTS-15 were observed in each case. 
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Figure 3. 2: Expression analysis of ADAMTS-15 and ADAMTS-15EA 
transfectants 
Expression analysis of representative stable transfectants of pcDNA3.1 (pc), 
ADAMTS-15 (15) and ADAMTS-15EA (15EA) in the LNCaP (A-B) and PC-3 (C-
D) cell lines, as indicated. Only representative clones used for subsequent analysis are 
shown. Cell lysates were subjected to Western blot analysis with the anti-Myc 
antibody to detect ADAMTS-15, ADAMTS-15EA expression and anti-GAPDH used 
as a loading control. The zymogen (z) and mature (m) forms of the enzymes are 
indicated. 
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3.4 Effect of ADAMTS-15 on cell proliferation and metabolism 
Individual clones were analyzed using the WST-1 proliferation assay. LNCaP cells 
expressing ADAMTS-15 showed a small but statistically significant decrease in absorbance 
at 48 h in comparison to pcDNA3.1 controls (Figure 3.3A), in contrast to those expressing 
ADAMTS-15EA that were comparable to the pcDNA3.1 controls at both time points (Figure 
3.3B). An even more pronounced effect was seen in PC-3 transfectants expressing 
ADAMTS-15 demonstrating a large and statistically significant decrease in absorbance at 
both 24 h and 48 h in comparison to the pcDNA3.1 controls (Figure 3.3C). Again no 
significant differences in absorbance was observed in cells expressing ADAMTS-15EA at 24 
h and 48 h compared to pcDNA3.1 controls (Figure 3.3D). This indicated that ADAMTS-15 
overexpression led to a significant inhibition of proliferation that was dependent on its 
catalytic activity. 
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Figure 3. 3: Proliferation analysis of ADAMTS-15 and ADAMTS-15EA 
transfectants 
Relative proliferation of LNCaP cells expressing ADAMTS-15 (A) or ADAMTS-
15EA (B) and PC-3 cells expressing ADAMTS-15 (C) or ADAMTS-15EA (D) in 
comparison to empty vector (pcDNA3.1) controls at the times indicated using the 
WST-1 method and measuring at 450 nm (*P<0.05, n= 3, pcDNA3.1 controls, n= 4 
ADAMTS-15 or ADAMTS-15EA transfectants).    
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Individual clones at sub-confluence were subjected to cell cycle analysis. LNCaP cells 
expressing ADAMTS-15 demonstrated no difference in their cell cycle profile compared to 
pcDNA3.1 controls (Figure 3.4A), whereas those expressing ADAMTS15EA showed a small 
increase in G stage in comparison to pcDNA3.1 controls (Figure 3.4B). No differences were 
observed in PC-3 cells expressing either ADAMTS-15 or ADAMTS-15EA in comparison to 
pcDNA3.1 controls (Figure 3.4C and D).  
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Figure 3. 4: Cell cycle profile of ADAMTS-15 and ADAMTS-15EA transfectants 
Cell cycle staging of LNCaP cells expressing ADAMTS-15 (A) or ADAMTS-15EA 
(B) and PC-3 cells expressing ADAMTS-15 (C) or ADAMTS-15EA (D) compared to 
pcDNA3.1 controls. In all cases A = apoptotic, G = growth phase, S = DNA synthesis 
phase, M = mitotic phase and O = other (**P<0.01, n= 3, pcDNA3.1 controls, n= 4 
ADAMTS-15 or ADAMTS-15EA transfectants).          
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Metabolic flux of individual clones was next analyzed using a Seahorse XF 3 extracellular 
analysis 24, which simultaneously measures cellular oxygen consumption rates (OCR) and 
extracellular acidification rates (ECAR), a proxy measure of glycolysis. Following 
assessment of basal bioenergetics, mitochondrial function was dissected through the 
sequential addition of oligomycin, FCCP, antimycin A and rotenone. Briefly, oligomycin 
blocks ATP synthases causing an initial decrease in the OCR to basal levels. Next FCCP is 
added resulting in the disruption of the proton gradient allowing oxygen to be maximally 
consumed. Spare respiratory capacity is measured as the difference between the maximal and 
basal respiration. Finally, addition of rotenone and antimycin A leads to the shutdown of 
basal complex 1 and 2 leading to complete mitochondrial arrest, but also allows the 
measurement of non-mitochondrial respiration (239). 
LNCaP cells expressing ADAMTS-15 showed an increase in both basal and maximal rates of 
glycolysis compared with pcDNA3.1 controls (Figure 3.5A). Interestingly, LNCaP cells 
expressing ADAMTS-15EA also showed increased basal but not maximal glycolytic rates 
when compared to pcDNA3.1 controls (Figure 3.5B). PC-3 cells expressing ADAMTS-15 
showed no significant differences in the basal or maximal glycolytic rate when compared to 
pcDNA3.1 controls (Figure 3.5C), which was also the case for PC-3 cells expressing 
ADAMTS-15EA in comparison to pcDNA3.1 controls (Figure 3.5D). 
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Figure 3. 5: Extracellular acidification rates in ADAMTS-15 and ADAMTS-
15EA transfectants 
Comparative ECAR of LNCaP cells expressing ADAMTS-15 (A) or ADAMTS-
15EA (B) and PC-3 cells expressing ADAMTS-15 (C) or ADAMTS-15EA (D) in 
comparison to pcDNA3.1 controls. ECAR rates were determined with Seahorse XF 3 
extracellular analysis 24 with basal rates demonstrating coupled respiration and 
maximal rates showing uncoupled respiration (*P<0.05, **P<0.01 and ***P<0.001, 
n= 3, pcDNA3.1 controls, n= 4, ADAMTS-15 or ADAMTS-15EA transfectants). 
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LNCaP cells expressing ADAMTS-15 also demonstrated increased uncoupled (Figure 3.6E) 
and basal complex 2 (Figure 3.6K) respiration in comparison to pcDNA3.1 controls, not seen 
in LNCaP cells expressing ADAMTS-15EA (Figure 3.6B, D, F, H, J, and L). PC-3 cells 
expressing ADAMTS-15 showed increased basal mitochondrial rate (Figure 3.7A), ATP 
turnover (Figure 3.7C), uncoupled respiration (Figure 3.7E), maximal respiration (Figure 
3.7G) and basal complex 1 (Figure 3.7I) in comparison to pcDNA3.1 controls. In contrast, 
decreased basal mitochondrial rate (Figure 3.7B), ATP turnover (Figure 3.7D) and basal 
complex 1 (Figure 3.7J) were observed in PC-3 cells expressing ADAMTS-15EA compared 
to pcDNA3.1 controls. Surprisingly, differences were observed between pcDNA3.1 controls 
in a pair wise manner in both LNCaP and PC-3 expressing both ADAMTS-15 and 
ADAMTS-15EA (Figure 3.6, E+F, G+H, K+L and 3.7, A+B, C+D, E+F, G+H, I+J, K+L).  
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Figure 3. 6: Oxygen consumption rates of LNCaP cells expressing ADAMTS-15 
and ADAMTS-15EA 
OCR of LNCaP expressing ADAMTS-15 (A, C, E, G, I, K) or ADAMTS-15EA (B, 
D, F, H, J, L): basal mitochondrial rate (A, B), ATP turnover (C, D), uncoupled 
respiration (E, F), maximal mitochondrial rate (G, H), basal complex 1 (I, J), basal 
complex 2 (K, L) in comparison to pcDNA3.1 controls. OCR results were determined 
by the use of Seahorse XF 3 extracellular analysis 24 (*P<0.05 and **P<0.01, n= 3, 
pcDNA3.1 controls, n= 4, ADAMTS-15 or ADAMTS-15EA transfectants). 
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Figure 3. 7: Oxygen consumption rates of PC-3 cells expressing ADAMTS-15 
and ADAMTS-15EA 
OCR of PC-3 expressing ADAMTS-15 (A, C, E, G, I, K) or ADAMTS-15EA (B, D, 
F, H, J, L): basal mitochondrial rate (A, B), ATP turnover (C, D), uncoupled 
respiration (E, F), maximal mitochondrial rate (G, H), basal complex 1 (I, J), basal 
complex 2 (K, L) in comparison to pcDNA3.1 controls. OCR results were determined 
by the use of Seahorse XF 3 extracellular analysis 24 (*P<0.05, **P<0.01, 
***P<0.001, n= 3, pcDNA3.1 controls, n= 4, ADAMTS-15 or ADAMTS-15EA 
transfectants). 
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3.5 Effect of ADAMTS-15 and ADAMTS-15EA on survival 
To gain further insight into the effects of ADAMTS-15 and ADAMTS-15EA overexpression, 
survival was examined using a flow cytometry based assay based on staining of phosphotidyl 
serine with FITC and detection of compromised cell membranes with PI staining. However, 
very little apoptosis was observed in any clones even under reduced serum (data not shown). 
Therefore, apoptosis was induced by treatment with sodium azide as described (240) for 24 h 
and apoptosis analyzed. Significant increases in the number of early and late stage apoptotic 
cells and dead cells, with a concomitant decrease in live cells, were detected in sodium azide 
treated LNCaP cells expressing ADAMTS-15 when compared to untreated cells. The 
increases in late stage apoptosis and dead cells was significantly higher than those in sodium 
azide treated pcDNA3.1 controls (Figure 3.8A). LNCaP cells expressing ADAMTS-15EA 
also demonstrated a significant increase in the number of dead cells upon sodium azide 
treatment, not seen in pcDNA3.1 controls. However, decreased early stage apoptosis was 
seen when compared to pcDNA3.1 controls (Figure 3.8B).  
PC-3 cells expressing ADAMTS-15 treated with sodium azide showed increased dead and 
early stage apoptotic cells and decreased living cells in comparison to those left untreated, 
with the changes in dead and living cells significantly different to pcDNA3.1 controls (Figure 
3.8C). There was also a small but statistically significant increase in the number of dead cells 
upon sodium azide treatment in ADAMTS-15EA clones not observed in untreated cells or 
pcDNA3.1 controls (Figure 3.8D).  
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Figure 3. 8: Apoptosis analysis of ADAMTS-15 and ADAMTS-15EA 
transfectants 
Analysis of apoptosis in sodium azide treated and untreated LNCaP cells expressing 
ADAMTS-15 (A) or ADAMTS15EA (B), and PC-3 cells expressing ADAMTS-15 
(C) or ADAMTS-15EA (D) compared to respective pcDNA3.1 controls. Apoptosis 
was quantified by staining with FITC and PI and assessing cells in the four quadrants: 
D = death, LS = late stage apoptosis, ES = early stage apoptosis, L = live cells (* 
P<0.05, **P<0.001, n=3, pcDNA3.1 controls, n= 4, ADAMTS-15 or ADAMTS-
15EA transfectants).  
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3.6 Effect of ADAMTS-15 and ADAMTS-15EA on chemosensitivity  
Individual clones were analyzed for chemosensitivity in a clinically-relevant setting by 
treating with the first line chemotherapeutic agent docetaxel (55). LNCaP transfectants 
exhibited only minor affects following docetaxel treatment (data no shown), and so the 
analysis focused on PC-3 clones. Docetaxel treatment of PC-3 transfectants led to an increase 
in the number of apoptotic, S phase, M phase and other cells, and a decrease in the G phase 
cells. However, no significant difference was observed between ADAMTS-15 clones and 
pcDNA3.1 controls (Figure 3.9A) or between PC-3 cells expressing ADAMTS-15EA when 
compared to pcDNA3.1 controls (Figure 3.9B), indicating unaltered chemosensitivity. 
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Figure 3. 9: Chemosensitivity of ADAMTS-15 and ADAMTS-15EA transfectants 
Cell cycle analysis of docetaxel treated and untreated PC-3 cells expressing 
ADAMTS-15 (A) or ADAMTS-15EA (B) compared to pcDNA3.1 controls. A = 
apoptotic, G =growth phase (G0 and G1), S = DNA synthesis phase, M = mitotic 
phase and O = other (*P<0.05, **P<0.01, ***P<0.001, n = 3, pcDNA3.1 controls, n= 
4, ADAMTS-15 or ADAMTS-15EA transfectants).   
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3.7 Effect of ADAMTS-15 and ADAMTS-15EA on migration  
The effects of ADAMTS-15 and ADAMTS-15EA overexpression on migration were 
evaluated using the established scratch “wound” healing assay (241). LNCaP clones were not 
able to be accurately assessed via this assay due to their clumping nature, and so the analysis 
was limited to the PC-3 cells (Figure 3.10). Significantly decreased cell migration was 
observed in the PC-3 cells expressing ADAMTS-15 when compared to pcDNA3.1 controls at 
both 6 h and 24 h post wounding. In comparison no significant differences were observed 
between PC-3 cells expressing ADAMTS-15EA and pcDNA3.1 controls. This suggested 
proteolytic activity-dependent role for ADAMTS-15 in suppressing cell migration. 
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Figure 3. 10: Migration of ADAMTS-15 and ADAMTS15EA transfectants 
Migration of PC-3 cells expressing ADAMTS-15 (A-B) and ADAMTS-15EA (C-D) 
compared to controls (pcDNA3.1) at the times indicated following wounding. Images 
represent representative images of cell migration with arrows highlighting the edge of 
migrating cells with dashes (#) demonstrating total wound closure (A&C), with 
percentage of migrating cells shown (B&D) (**P< 0.01, n= 3, pcDNA3.1 controls, n= 
4, ADAMTS-15 or ADAMTS-15EA transfectants). 
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3.8 Effect of ADAMTS-15 on migration pathways  
The significant decrease of migration in PC-3 cells expressing ADAMTS-15 (2.3.7) led to 
further investigation of specific migration pathways. Briefly, Qiagen RT-PCR arrays were 
employed to determine alterations in games linked to human cell motility, comparing PC-3 
cells expressing ADAMTS-15 to pcDNA3.1 controls. Interestingly, a number of genes were 
up-regulated, with the Ezrin-encoding gene noted to have the highest fold change, while the 
gene encoding protein kinase 2 was one of several down-regulated (Figure 3.11).    
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Figure 3. 11: Effect of ADAMTS-15 expression on migratory pathways 
Relative (fold change) of genes associated with migration in PC-3 cells expressing 
ADAMTS-15 in comparison to cells expressing pcDNA3.1 controls, showing all 
genes (A) and those with a significant change (B) (P<0.001, n= 1).  
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3.9 Discussion 
There is little knowledge regarding the role of ADAMTS-15 in PrCa. Therefore, this Chapter 
explored the effects of ADAMTS-15 overexpression in the LNCaP and PC-3 cell lines, being 
representative of the androgen-responsive and castrate-resistant stages of PrCa respectively. 
To gain further mechanistic insight, a metalloproteinase-inactive form of ADAMTS-15 was 
also expressed, and in all cases comparisons were made to empty vector (pcDNA3.1) 
controls. Investigations looked at some key hallmarks of cancer including: proliferation, 
metabolism, survival, apoptosis, chemoresistance and migration. 
Proliferation is an essential aspect of tumorigenesis, previous investigations have examined 
the effects of ADAMTS-15 on proliferation in breast cancer cell lines but no effects were 
noted (219). In this Chapter, proliferation was assessed using the WST-1 assay which 
activates the breakdown of a tetrazolium salt and subsequent colour change is used as a 
measure of proliferation. Decreased proliferation was observed in both LNCaP and PC-3 
cells overexpressing ADAMTS-15 but not those expressing ADAMTS-15EA, which suggests 
that the effect was dependent on the catalytic activity of the enzyme. No significant effects on 
the cell cycle were found.  
Altered metabolism represents another hallmark of cancer. Cancer cells characteristically 
utilize glycolysis to perform ATP synthesis despite the low yield of ATP, a process known as 
the Walburg effect, which is also thought to be an indicator of high grade tumors (242, 243). 
Cancer cells also require metabolic reprogramming to support elevated synthesis of DNA, 
phospholipids and protein (244). Cell metabolism was investigated through the use of a 
Seahorse bioscience XF 24. LNCaP cells expressing either ADAMTS-15 or ADAMTS-15EA 
showed increased basal respiration compared to controls suggesting ADAMTS-15 was able 
to regulate the glycolysis of these cells independently of enzyme activity. No significant 
differences were observed in PC-3 transfectants.  
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LNCaP cells expressing ADAMTS-15 showed increased uncoupled respiration and basal 
complex 2 in comparison to pcDNA3.1 controls, whereas those expressing ADAMTS-15EA 
showed no differences in comparison to pcDNA3.1 controls. PC-3 cells expressing 
ADAMTS-15 showed increased basal mitochondrial rate, ATP turnover, uncoupled 
respiration, maximal respiration and basal complex 1 in comparison to pcDNA3.1 controls. 
Notably, PC-3 cells expressing ADAMTS-15EA demonstrated the opposite effect with 
down-regulations of basal mitochondrial rate, ATP turnover and basal complex 1 observed. 
Previous investigation in breast cancer cell lines have demonstrated increased basal rate and 
ATP turnover to correlate with an increased metastatic state (245). Furthermore, the basal 
rate is noted to be highly controlled by ATP turnover which can be chemically inhibited 
leading to an increase in glycolysis complementing uncoupled respiration and maximal 
respiration leading to a glycolytic state in cells as observed in the PC-3 cells expressing 
ADAMTS-15 (239, 245).  
Enhanced cell survival-typically through evasion of apoptosis-represents another hallmark of 
cancer progression (246). ADAMTS-2, -5, and -9 have previously been demonstrated to 
induce apoptosis (200). However, in a previous study ADAMTS-15 overexpression did not 
alter apoptosis in breast cancer cell lines (219). Since very low rates of apoptosis were 
observed under standard conditions, treatment with sodium azide was used to induce 
apoptosis of the various transfectants (240). Significant induction of early and late stage 
apoptosis was observed in LNCaP cells treated with sodium azide expressing ADAMTS-15, 
but not in cells expressing ADAMTS-15EA when compared to untreated cells. No 
differences were observed in pcDNA3.1 controls when treated with sodium azide. Similarly 
PC-3 cells treated with sodium azide expressing ADAMTS-15 demonstrated an increase in 
early stage apoptosis which was not observed in cells expressing ADAMTS-15EA when 
compared to untreated cells. This suggests that when physiologically challenged, the catalytic 
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activity of ADAMTS-15 contributed to the induction of apoptosis, similar to what was 
observed with ADAMTS-2, -5 and -9. 
Another major hallmark of cancer is altered chemosensitivity. The gold standard 
chemotherapeutic agent for PrCa treatment is docetaxel (53-55) and so the potential for 
ADAMTS-15 to impact on sensitivity to this agent was evaluated. Docetaxel is known to 
cause destabilization of microtubules resulting in M phase arrest and so cell cycle analysis 
was performed. Docetaxel treatment of PC-3 clones elicited increased cells in M phase and to 
a lesser extent S phase, as well as decreased cells in G phase and apoptotic cells. However, no 
difference was observed between PC-3 cells expressing ADAMTS-15 and pcDNA3.1 
controls, suggesting ADAMTS-15 is not involved in chemosensitivity. 
 Cell migration represents a critical step in tumor metastasis, allowing cells to migrate to 
secondary sites via blood or lymphatics (247). Unfortunately, the LNCaP cell lines could not 
be analyzed by scratch ‘wound’ migration due to their propensity for clumping and so it was 
not possible to determine if this phenotype was also relevant for early stage PrCa. However, 
PC-3 cells expressing ADAMTS-15 showed a significant decrease in migration when 
comparing to those expressing ADAMTS-15EA or control clones. This suggests that the 
metalloproteinase domain of ADAMTS-15 contributes to reduced cell migration, and so 
likely less metastasis. This is consistent with several other studies. ADAMTS-15 expression 
in colorectal cancer cells led to decreased tumor invasion when compared to mutated 
ADAMTS-15 or control cell lines (218). Expression of ADAMTS-15 in breast cancer has 
also been shown to significantly inhibit cell migration, although in this case the 
metalloproteinase-inactive isoform also decreased cell migration suggesting ADAMTS-15 
could act independently of its catalytic activity in breast cancer cell migration (219).  
Analysis of migration pathways in PC-3 cells showed ADAMTS-15 expression affected the 
expression of several genes that could help explain the reduced migration. These included 
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increased Ezrin, known to act as a linker protein between membrane proteins and actin 
cytoskeleton (248) and Cofilin, known to decrease actin polymerisation (249), and decreased 
PTK2 and PLCγ1, both of which have been shown to promote motility/metastasis (250, 251).     
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Chapter 4 ~ Investigation of ADAMTS-15 in a 
NOD/SCID mouse prostate cancer xenograft model 
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4.1 Overview 
Models for investigating PrCa in vivo are limited, with no single model demonstrating the 
same clinical features as observed in men. The NOD/SCID immunodeficient mouse model 
lacks functional T, B and NK cells, meaning tumor xenografts are well tolerated when 
subcutaneously injected, leading to efficient tumor growth (252). This model has been 
previously utilized for PrCa research (253) and also for studies on other cancers including 
those examining the role of ADAMTS-15 (218, 219). Therefore, to extend the in vitro results 
obtained in Chapter 3, this model was used to investigate the role of ADAMTS-15 expression 
in PrCa in vivo.  
Androgens play an important role in PrCa etiology (50, 254, 255). ADAMTS-15 expression 
has previously been shown to be regulated by androgens at both the mRNA and protein levels 
(256). Moreover, the results presented in Chapter 3 identified differences in the effects of 
ADAMTS-15 on androgen-responsive compared to castrate-resistant cells. Therefore, the 
potential for androgens to influence the effects of ADAMTS-15 was also investigated. This 
Chapter describes studies in which LNCaP and PC-3 cells expressing ADAMTS-15 or 
ADAMTS-15EA or transfected with pcDNA3.1 were injected subcutaneously into male 
NOD/SCID mice, with a subset of these mice castrated before injection of the androgen-
responsive LNCaP cell line to investigate the potential role of androgens.  
4.2 Growth of LNCaP lines in uncastrated NOD/SCID mice 
LNCaP cell lines stably expressing ADAMTS-15 or ADAMTS-15EA or pcDNA3.1 
containing controls were subcutaneously injected into the left flank of uncastrated male 
NOD/SCID mice. Mice were allowed to recover with full access to water and food. Weight 
and formation of palpable tumors were monitored daily and calipers were used to measure 
tumor size once detected, with mice euthanized once the tumor volume reached 15mm3.  
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Mice injected with LNCaP cells expressing ADAMTS-15 showed a significant decrease in 
tumor growth rate in comparison to those injected with cells transfected with pcDNA3.1 
controls, with a similar decreased tumor growth rates also observed in mice injected with 
ADAMTS-15EA expressing clones (Figure 4.1A). It was also noted, that tumors extracted 
from mice injected with LNCaP cells expressing ADAMTS-15 and ADAMTS-15EA tended 
to consists of a single tumor mass compared to pcDNA3.1 controls that tended to be more 
lobular (Figure 4.1B). Interestingly, mice injected with ADAMTS-15 expressing cells 
showed significantly increased survival, with this cohort reaching the tumor endpoint 
approximately 30 days later than those injected with ADAMTS-15EA expressing cells or 
pcDNA3.1 controls (Figure 4.1C). This suggested that ADAMTS-15 exerts a protective 
function that is dependent on its catalytic activity. 
Tumors were sectioned and analyzed with respect to two key hallmarks of cancer: 
proliferation as assessed with anti-Ki-67, and apoptosis as assessed with anti-Caspase 3. 
Tumors from mice injected with ADAMTS-15 or ADAMTS-15EA expressing LNCaP cells 
showed reduced anti-Ki-67 staining in comparison to those from mice injected with controls 
(Figure 4.2B). Alternatively, anti-Caspase 3 staining was not statistically different between 
groups (Figure 4.2C).  
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Figure 4. 1: Tumor growth rate and mortality of uncastrated male NOD/SCID 
mice injected with LNCaP xenografts 
Growth rate of tumors from uncastrated male NOD/SCID mice injected with LNCaP 
cells expressing ADAMTS-15 or ADAMTS-15EA compared to pcDNA3.1 controls 
(A). Representative images of extracted tumors expressing ADAMTS-15 or 
ADAMTS-15EA or pcDNA3.1 controls (B). Survival of mice bearing tumors 
expressing ADAMTS-15 or ADAMTS-15EA or pcDNA3.1 controls (C). Statistical 
significance is shown in all cases relative to pcDNA3.1 controls (*P<0.05, 
***P<0.001, n= 10, scale bar = 1.25 cm). 
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Figure 4. 2: Analysis of proliferation and apoptosis in LNCaP xenograft tumors 
from uncastrated mice 
Representative images of tumor sections from uncastrated male NOD/SCID mice 
injected with LNCaP expressing ADAMTS-15 or ADAMTS-15EA or pcDNA3.1 
controls, stained with anti-Ki-67 as a proliferation marker or anti-Caspase 3 as an 
apoptosis marker as indicated (A). The area of staining was assessed by Image J 
analysis for anti-Ki-67 (B) or anti-Caspase 3 (C) for the indicated tumor groups 
(***P<0.001, n= 3, scale bar= 10 μm).  
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4.3 Growth of LNCaP lines in castrated NOD/SCID mice 
To explore the potential effects of androgens, male NOD/SCID mice were surgically 
castrated prior to subcutaneous injection with LNCaP cells stably expressing ADAMTS-15 or 
ADAMTS-15EA or pcDNA3.1 transfected controls cells. Tumor growth rates were again 
significantly decreased in mice injected with ADAMTS-15 expressing cells compared to 
control pcDNA3.1 transfectants, but tumor growth of ADAMTS-15EA expressing 
transfectants was statistically different to the control cells (Figure 4.3A). No differences in 
the appearance of the tumors were noted with all tumors appearing lobulated (Figure 4.3B). 
Importantly, no significant differences were observed in the survival of mice injected with 
LNCaP cells expressing ADAMTS-15 or ADAMTS-15EA or pcDNA3.1 controls (Figure 
4.3C). This indicated that the protective effects of ADAMTS-15 were dependent on 
androgens.  
These tumors were also analyzed with respect to proliferation or apoptosis through anti-Ki-67 
and anti-Caspase 3 markers respectively. Preliminary data indicated no statistically 
significant differences in proliferation (Figure 4.4B) or apoptosis (Figure 4.4C) in tumors 
from castrated mice injected with LNCaP expressing ADAMTS-15 in comparison to LNCaP 
expressing ADAMTS-15EA or pcDNA3.1 controls.  
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Figure 4. 3: Tumor growth rate and mortality of castrated male NOD/SCID mice 
injected with LNCaP xenografts 
Growth rate of tumors from castrated male NOD/SCID mice injected with cells 
expressing ADAMTS-15 or ADAMTS-15EA or pcDNA3.1 controls (A). 
Representative images of extracted tumors expressing ADAMTS-15 or ADAMTS-
15EA or pcDNA3.1 controls. Survival of mice bearing tumors expressing ADAMTS-
15 or ADAMTS-15EA or pcDNA3.1 controls (C) (***P<0.001, n= 10, scale bar = 
1.25 cm).    
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Figure 4. 4: Analysis of proliferation and apoptosis in LNCaP xenograft tumors 
from castrated mice 
Representative images of tumor sections from castrated male NOD/SCID mice 
injected with LNCaP expressing ADAMTS-15 or ADAMTS-15EA or pcDNA3.1 
controls stained with anti-Ki-67 as a proliferation marker or anti-Caspase-3 as an 
apoptosis marker as indicated (A). The area of staining was assessed with Image J 
analysis for anti-Ki-67 (B) or anti-Caspase 3 (C) for the indicated tumor groups (n= 3, 
scale bar= 10 μm). 
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4.4 Growth of PC-3 cells in NOD/SCID mice 
PC-3 cells stably expressing ADAMTS-15 or ADAMTS-15EA along with pcDNA3.1 
controls were also subcutaneously injected into the left flank of NOD/SCID mice. 
Unfortunately, tumors failed to consistently take in these mice with only a single injected 
mouse developing a detectable tumor, which was positive for anti-Myc staining (data not 
shown) making it impossible to draw any significant conclusions. 
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4.5 Discussion 
The results of Chapter 3 indicated roles for ADAMTS-15 in PrCa cell growth, survival and 
migration in vitro. This Chapter extended these studies in vivo using the NOD/SCID 
xenograft model. The original plan was to study both the LNCaP and PC-3 cell lines as 
representatives of the early androgen-responsive and late castrate-resistant PrCa stages, 
respectively. However, only the LNCaP cell lines elicited robust tumor development.  
Un-castrated mice injected with LNCaP cells expressing ADAMTS-15 demonstrated 
significantly increased survival in comparison to those injected with ADAMTS-15EA or 
pcDNA3.1 control cells. Furthermore, the tumor growth rates of tumors expressing 
ADAMTS-15 was significantly decreased compared to pcDNA3.1 controls, with ADAMTS-
15EA also having a decreased tumor growth rate. This is consistent with a previous study 
showing knock-down of ADAMTS-15 in colon cancer cells led to increased subcutaneous 
tumor growth in NOD/SCID mice (218). Collectively, these results are strongly suggestive of 
a tumor suppressor role for ADAMTS-15 although the requirement for its catalytic activity 
remains less clear. 
Androgens have been shown to be a critical component of PrCa biology. Androgens are 
required for localized early PrCa growth (8), but this requirement disappears concomitantly 
with the acquisition of aggressive cancer phenotypes associated with metastasis (8, 10, 11). 
The main circulating androgen is testosterone which is primarily secreted by the testes and 
bound to albumin and sex hormone binding globulin. Testosterone is able to enter prostate 
cells and is then converted to DHT by 5α-reductase, which is then able to activate the 
androgen receptor (257). Treatment of PrCa through androgen ablation has been shown to be 
successful over the short term in early-stage tumors, but typically androgen-resistance 
eventuates (44).  
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The importance of androgens was investigated by parallel injection of LNCaP transfectants 
into castrated mice. In this setting mice injected with cells expressing ADAMTS-15 showed 
no survival advantage when compared to those injected with LNCaP cells expressing 
ADAMTS-15EA or pcDNA3.1 controls despite the fact that tumor growth rate remained 
suppressed. This suggests that androgen ablation impairs a protective function of ADAMTS-
15. Interestingly, previous investigations found that ADAMTS-15 expression was negatively 
regulated by DHT (256), meaning such an effect in a clinical setting might be counteracted 
by increased levels of endogenous ADAMTS-15 following castration. 
Two hallmarks of cancer are enhanced proliferation and reduced apoptosis. These were 
investigated in tumors dissected from the mice by analyzing expression of Ki-67 and Caspase 
3, respectively. Those from uncastrated mice injected with LNCaP expressing ADAMTS-15 
showed decreased proliferation and increased apoptosis in comparison to pcDNA3.1 controls, 
consistent with their decreased growth rates. This data also aligns with the in vitro work 
described in Chapter 3 where decreased proliferation and increased apoptosis was observed in 
LNCaP and PC-3 cells expressing ADAMTS-15 in comparison to pcDNA3.1 controls. The 
results from ADAMTS-15EA expressing tumors were more equivocal. Moreover, castrated 
mice injected with LNCaP cells expressing ADAMTS-15 showed no difference in 
proliferation or apoptosis in comparison to ADAMTS-15EA or pcDNA3.1 controls despite 
reduced tumor growth rate. This requires further investigation to full understand. 
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Chapter 5 ~ Localization of ADAMTS-15, versican 
and versikine in patient prostate cancer biopsies.  
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5.1 Overview 
Limited information is available regarding ADAMTS-15 expression in PrCa, with the 
majority of investigations examining expression in representative cell lines (181). VCAN has 
been shown to accumulate during PrCa progression, correlating with a worse prognosis for 
the patient (63, 140-146). Other studies have demonstrated that VCAN levels can be 
regulated by ADAMTS-15 with VCAN cleavage leading to the production of versikine, a 
potential bioactive cleavage fragment (94, 99), albeit not in PrCa. This Chapter investigated 
the potential interaction of ADAMTS-15 and VCAN by analyzing the expression of 
ADAMTS-15 in human prostate biopsies and its co-localization with VCAN and versikine.  
5.2 Localization of ADAMTS-15, of VCAN and versikine in prostate cancer 
biopsies 
In preliminary experiments, ADAMTS-15 expression was examined by immunofluorescence 
with anti-ADAMTS-15 in a set of PrCa biopsies ranging from low to high grade PrCa. The 
anti-ADAMTS-15 antibody was previously validated and published by previous lab members 
Dancevic et al and Stupka et al (94, 134).Increased levels of ADAMTS-15 were consistently 
observed in high grade compared to low grade samples, with expression observed in both 
epithelial and stromal tissues (Figure 5.1).  
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Figure 5. 1: Expression of ADAMTS-15 in prostate cancer biopsies 
Representative images of low and high grade PrCa specimens subjected to 
immunofluorescence with anti-ADAMTS-15 (red) and DAPI staining of nuclei (aqua) 
Control slides were processed identically but without the primary antibody. Epithelial 
staining is indicated with an arrow and stromal staining with arrowhead, with scale 
bars at 60 µm. Representative image of 5 sections from multiple PrCa biopsies (n= 6). 
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Encouraged by these results, PrCa biopsies from Gleason grade 6-9 were subjected to 
immunofluorescence with anti-ADAMTS-15 and either anti-VCAN (GAGβ) (Figure 5.2) or 
anti-versikine (V0/V1 neo) (Figure 5.3). Validation of VCAN and versikine antibodies was 
previously carried out by past lab members and published, Stupka et al (134).Expression of 
all 3 proteins was predominantly localized to the epithelium of glands where cells were 
enlarged often containing more than one nucleus with disappearance of a basal cell layer.  
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Figure 5. 2: Expression and co-localization of ADAMTS-15 and versican in 
prostate cancer biopsies 
Expression of ADAMTS-15 (green) and VCAN (red) in representable PrCa biopsies 
of the indicated Gleason grade detected by immunofluorescence, along with DAPI 
staining of the nuclei (blue). A merged image is provided with arrows indicating areas 
of co-localization. Scale bars are 60 µm and 100 µm in size, n= 22. 
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Figure 5. 3: Expression and co-localization of ADAMTS-15 and versikine in 
prostate cancer biopsies 
Expression of ADAMTS-15 (green) and versikine (red) in representable PrCa 
biopsies of the indicated Gleason grade detected by immunofluorescence, along with 
DAPI staining of the nuclei (blue). A merged image is provided with arrows 
indicating areas of co-localization. Scale bars are 60 µm and 100 µm in size. 
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Expression was quantified using Image J software. ADAMTS-15 expression was 
significantly increased from tumor grade 6-8, but was diminished in Gleason grade 9 
specimens (Figure 5.4A). By comparison, VCAN showed significantly increased expression 
in Gleason grade 7B samples compared to all other grades (Figure 5.4B). In contrast, 
versikine expression was most highly expressed in Gleason grade 8 samples, coincident with 
peak ADAMTS-15 expression, suggesting the latter may be a regulator of versikine levels 
through VCAN cleavage.  
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Figure 5. 4: Quantification of area of expression of ADAMTS-15, versican and 
versikine 
Area of expression of ADAMTS-15 (A), VCAN (B) and versikine (C) in the 
indicated Gleason grade as determined by Image J analysis. Gleason grade 7 and 9 are 
presented as A and B, corresponding to the area of lower and higher grading, 
respectively (**P<0.01, ***P<0.001, n= 22).   
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5.3 Co-localization of ADAMTS-15 with versican and versikine in prostate 
cancer biopsies 
Co-localization of ADAMTS-15 with both VCAN (Figure 5.2) and versikine (Figure 5.3) 
was observed. Co-localization was quantified through the use of Pearson’s co-efficient and 
Mander’s overlap with a score of one representing 100% co-localization. Strong co-
localization of ADAMTS-15 and VCAN was evident, with maximum co-localization in 
Gleason grade 7 samples compared to Gleason grade 6, 8 and 9 samples (Figure 5.5A and B). 
Strong co-localization of ADAMTS-15 and versikine was also evident in Gleason grade 7 
samples when compared to Gleason grade 6, 8 and 9 (Figure 6.6A and B). Interestingly 
versikine was found to be localized to the nucleus in Gleason grade 6 cells a phenomenon 
which has not previously been reported.  
 
 
 
 
 
 
 
  
117 
 
 
 
 
 
 
 
 
 
 
Figure 5. 5: Quantification of co-localization of ADAMTS-15 and versican in 
prostate cancer biopsies 
Co-localization of ADAMTS-15 and VCAN in the indicated Gleason grade PrCa 
biopsies was determined by Image J analysis of slides such as those represented in 
Figure 5.2 and assessment of the overlap using Pearson’s correlation (A) or Mander’s 
overlap (B). Gleason grade 7 and 9 are presented as A and B, corresponding to the 
area of lower and higher grading, respectively (*P<0.05, **P<0.01, ***P<0.001, n= 
22).   
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Figure 5. 6: Quantification of co-localization between ADAMTS-15 and versikine 
in prostate cancer 
Co-localization of ADAMTS-15 and versikine in the indicated Gleason grade PrCa 
biopsies was determined by Image J analysis of slides represented in Figure 5.3 and 
examination of overlap using Pearson’s correlation (A) or Mander’s overlap (B). 
Gleason grade 7 and 9 are presented as A and B, corresponding to the area of lower 
and higher grading, respectively (**P<0.01, ***P<0.001, n= 22).   
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5.5 Discussion 
VCAN accumulation has been shown to correlate with increased PrCa grade and a worse 
prognosis for patients (143-145, 168). Furthermore, ADAMTS-15 is known to regulate 
VCAN expression by cleaving VCAN prior to the GAG-β region forming a bioactive 75 kDa 
product, versikine (94, 99). The role and function of versikine is limited in cancer research 
with investigations predominantly focusing on early stage development (99), however 
versikine has been implicated in myeloma progression through VCAN cleavage regulating 
inflammatory responses acting in a tumor suppressive manner (100). Moreover, the 
possibility of versikine being soluble with potential interactions with other tissues is an 
exciting area of research which requires further investigations with ADAMTS-15 already 
having expression in both breast and colorectal cancers (258). 
Further investigations are required to determine if a similar role could be occurring in PrCa. 
Information regarding expression of ADAMTS-15, VCAN and versikine in PrCa biopsies is 
limited, with no data on potential co-localization. Therefore, this Chapter focused on 
elucidating the expression and co-localization of ADAMTS-15, VCAN and versikine in 
Gleason grade 6-9 PrCa biopsies using immunofluorescence. Alternatively, lower grades of 
PrCa biopsies were unable to be collected due to many men not electing this as a treatment 
option. 
Increased accumulation of ADAMTS-15 was observed in epithelial tissue of higher grade 
tumors with the highest expression detected in Gleason grade 8 samples. Interestingly, 
ADAMTS-15 expression was reduced in Gleason grade 9 samples. Whether this relates to 
loss of androgen-medicated ADAMTS-15 expression, promoter methylation, or other causes 
remains to be determined. Highest expression of VCAN was observed in Gleason grade 7 
samples. Importantly, ADAMTS-15 and VCAN were found to be statistically co-localized in 
all grades, but was highest in Gleason grade 7 samples when compared to samples of grades 
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6, 8 and 9. Further to this decreased VCAN expression was observed in Gleason grade 8 
samples, in which maximum versikine expression was with strong co-localization between 
ADAMTS-15 and versikine also observed. This is consistent with the hypothesis that 
ADAMTS-15 acts to cleave VCAN in PrCa, thereby forming versikine.    
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Chapter 6 ~ Discussion and future 
directions 
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6.1 Overview 
Approximately 1 in 7 men will be diagnosed with PrCa in their lifetime and despite advances 
in early detection and treatment, this disease remains a major burden on society (4, 259). 
Emerging as a key player in cancer progression generally is the regulation of the ECM, 
particularly through the hyalectan protein VCAN (62, 80, 81). This is also likely to be 
important in PrCa, with VCAN expression known to be up-regulated during PrCa progression 
and linked to poor prognosis (143-145, 168). Members of the ADAMTS family of 
proteoglycanases are involved in ECM regulation, with ADAMTS-1, -4, -5, -9, -15 and -20 
known to cleave VCAN (94-97). Several family members have also been shown to have an 
impact on cancer progression (133, 137).  
The objective of this Thesis was to investigate a potential role for ADAMTS-15 in PrCa. 
Studies were conducted using relevant cell models in vitro and in vivo and also on patient 
biopsies. It was hypothesized that this work would generate new insights into PrCa biology 
including its molecular etiology.  
6.2 Effects of ADAMTS-15 overexpression on prostate cancer phenotypes 
PrCa cell lines have been widely used in research and have provided important information 
about androgen regulation (248, 254), migration (260), proliferation (261), apoptosis (240, 
262), treatment modalities (263) and signalling pathways (264, 265). The cell lines LNCaP 
and PC-3 are representative of the androgen-responsive and castrate-resistant stages of PrCa, 
respectively, and were chosen for this study to provide a broad perspective of the effects of 
ADAMTS-15.  
ADAMTS proteases are multi-domain polypeptides with most research focusing on their 
catalytic activity, although non-catalytic roles have been identified (203, 212, 219, 266). 
Endogenous expression of ADAMTS-15 was detected via RT-PCR in both LNCaP and PC-3 
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cells. To consider both catalytic and non-catalytic functions, LNCaP and PC-3 cell lines 
stably expressing wild-type ADAMTS-15 or the metalloproteinase-inactive ADAMTS-15 
(ADAMTS-15EA) using the pcDNA3.1 expression plasmid were generated and characterized 
in vitro and in vivo. Investigations focused on several key hallmarks of cancer including: 
proliferation, apoptosis, chemosensitivity, migration and metabolism (244).  
Overexpression of ADAMTS-15 but not ADAMTS-15EA caused a significant decrease in 
proliferation and also reduced survival in both LNCaP and PC-3 cells. This indicates that the 
metalloproteinase activity of ADAMTS-15 is required to mediate negative regulation of 
proliferation and survival in PrCa. This result contrasted with a study in breast cancer in 
which ADAMTS-15 expression did not affect either proliferation or apoptosis (219).  
The effects of ADAMTS-15 on cell metabolism have not been extensively examined. 
Interestingly, expression of ADAMTS-15 but not ADAMTS-15EA resulted in increased 
glycolysis in PC-3 cells, whereas expression of either ADAMTS-15 or ADAMTS-15EA 
increased glycolysis in LNCaP cells. Expression of ADAMTS-15 but not ADAMTS-15EA 
up-regulated basal mitochondrial rate, ATP turnover, uncoupled respiration, maximal 
mitochondrial rate and basal complex one in PC-3 cells, resulted in increased uncoupled 
respiration and basal complex 2 in LNCaP cells. Collectively, this suggests that ADAMTS-15 
expression is increasing metabolism, which appears largely dependent on its catalytic 
function. Combined with the data indicating decreased proliferation, this points to ADAMTS-
15 exerting an anabolic function, which represents a key characteristic of cancer cells (244).  
For technical reasons migration could only be assessed in the PC-3 cell line, but these studies 
showed that expression of ADAMTS-15 but not ADAMTS-15EA significantly decreased 
migration. This was partially in agreement with previous research in breast cancer, which 
also demonstrated decreased migration in ADAMTS-15 expressing cell lines. However, a 
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similar result was observed in ADAMTS-15EA expressing cell lines, indicating migration 
was not dependent on catalytic activity in these cells (219).  
Furthermore, due to the contrasting difference between ADAMTS-15 and ADAMTS-15EA 
further research could include knocking-down expression of ADAMTS-15 and repeat current 
experiments looking at the key hallmarks of cancer. 
Further investigations into potential molecular mediator revealed increased expression of 
Ezrin and Cofilin as a result of ADAMTS-15 overexpression. Ezrin plays a key role in 
maintaining architectural integrity of cells by linking plasma membrane proteins to the 
cortical actin cytoskeleton (267). This protein has been shown to regulate epithelial-
mesenchymal transition and metastasis in cervical cancer (268). In PrCa, Ezrin has also been 
implicated in cell motility, but this was activation-dependent (269), suggesting that simply 
increasing its expression may not impact on migration. Cofilin-1 regulates actin dynamics 
which also drives cell motility (270), but its exact role is still unclear. Overexpression of 
Cofilin-1 has been shown to suppress invasion (and growth) of non-small cell lung cancer 
(271), but its knock-down increased migration of breast cancer cells (272). Indeed in PrCa 
Cofilin phosphorylation status appears critical, with phosphorylated Cofilin associated with 
reduced invasion and dephosphorylated Cofilin with enhanced metastasis (273). In addition, 
reduced expression of protein tyrosine kinase 2 and phospholipase D2 was observed as a 
result of ADAMTS-15 expression. This is easier to interpret, since both have been identified 
as key drivers in cell migration as well as having anti-apoptotic roles (250, 251, 274, 275), 
consistent with the decreased migration and increased apoptosis observed as a result of 
ADAMTS-15 overexpression.  
Further research is required to explore the molecules mediating the effects of ADAMTS-15 
on proliferation, apoptosis and anabolism as performed for migration. Detailed examination 
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of the role played by the proteins identified is then essential. This could be achieved by 
knock-down and/or overexpression in the PrCa models described in this Thesis. 
NOD/SCID mice have been widely employed to study PrCa in vivo and were used to extend 
the in vivo studies. Mice injected with LNCaP cells expressing ADAMTS-15 but not those 
expressing ADAMTS-15EA showed increased survival compared to those injected with 
control cells. This correlated to some extent with concomitant reduction in tumor growth rate. 
Together, these data suggest that ADAMTS-15 may act as a putative tumor suppressor gene 
through its catalytic activity. 
The in vivo model in this work only examined localized tumor growth and survival. 
Metastatic xenograft models also exist (276-279), which would allow examination of this 
aspect of cancer biology. Moreover, the data presented only examined the effects of 
ADAMTS-15 overexpression, which would be complemented by investigating the effects of 
ADAMTS-15 knock-down. The work could also be extended to analyse the xenografts in 
Adamts-15 knock-out mice on a NOD/SCID background to assess the role of ADAMTS-15 
in non-tumor cells. 
6.3 ADAMTS-15, VCAN and versikine expression in PrCa biopsies 
Data regarding ADAMTS-15 expression in PrCa is largely limited to studies in cell lines, 
with expression analysis of primary tumors particularly lacking. Therefore, the expression of 
ADAMTS-15 along with VCAN and its cleavage product versikine was evaluated in a range 
of PrCa biopsies. ADAMTS-15 expression was shown to be increased in high Gleason grade 
PrCa, consistent with a previous study showing increased expression of ADAMTS-15 in late 
stage PrCa cell lines (181). Importantly, ADAMTS-15 co-localized to a significant extent 
with both VCAN and versikine in high grade biopsies, with VCAN decreasing and versikine 
increasing in Gleason grade 8 biopsies. This is consistent with ADAMTS-15 potentially 
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acting to cleave VCAN to form versikine. Further to this higher powered magnification 
would be advantageous to decipher between tissue stroma and tumor cells.  
ADAMTS regulation of VCAN is an exciting area of research with the role of versikine in 
cancer of considerable interest. Overexpression or ablation of VCAN, or addition of 
versikine, in the PrCa cell lines used in this study would be a useful starting point for future 
experiments. The analysis of PrCa biopsies should also be expanded to explore other 
potential players. These include other ADAMTS family members, or other ECM regulators, 
such as MMPs, ADAMS and TIMPS, as well as genes identified in the pathway analysis. 
Finally, these studies could be extended to look at possible mutation of the various genes 
under consideration. 
6.4 Androgen effects  
The androgen axis is a critical contributor to PrCa progression with several current treatment 
modalities targeting androgens. The potential effects of androgen were assessed in the in vivo 
NOD/SCID mouse model by the parallel analysis of a castrated cohort of mice injected with 
androgen-responsive LNCaP cell lines. Interestingly, in contrast to uncastrated mice, no 
significant differences in survival or tumor growth rate were observed in castrated mice 
injected with LNCaP expressing ADAMTS-15 compared to those expressing ADAMTS-
15EA or pcDNA3.1 controls. This indicates that in the absence of androgens the protective 
effect of ADAMTS-15 expression was lost. 
 Further studies are required to understand the interplay between androgens and ADAMTS-
15. These could include in vitro studies with the androgen-responsive LNCaP cells, to 
investigate how androgens impact on the phenotype changes mediated by ADAMTS-15 
overexpression including angiogenesis. They could also involve analysis of castrate-resistant 
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PC-3 cell transfectants in the NOD/SCID model. Additionally, analysis of interactions 
between ADAMTS-15, VCAN and androgens would be important. 
6.5 Conclusions 
The data presented in this Thesis suggest that ADAMTS-15 acts as a tumor suppressor in 
PrCa, impacting on proliferation, migration and survival-with its effects dependent on 
catalytic activity and influenced by androgens. The results also support regulation of VCAN 
by ADAMTS-15, likely generating the cleaved fragment versikine, which may contribute to 
the tumor suppressive function. This data collectively provide several new insights into the 
role of ADAMTS-15 in PrCa progression. It is also warrants additional studies to explore the 
nexus between ADAMTS-15, androgens and VCAN/versikine, which may provide additional 
understanding, which might inform new approaches to therapy or diagnosis. 
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Appendix I 
 
 
 
Figure 6. 1: Endogenous expression of ADAMTS-15 
Endogenous expression of ADAMTS-15 and β-actin in LNCaP (A) and PC-3 (B) cell 
lines. (L: ladder, C: cell sample) 
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